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Abstract 
 
Nucleic Acids are unique biopolymers capable of encoding and transferring genetic information 
from one generation to the next for every form of life. This fascinating property has made them 
the topic of intense research from a variety of aspects. Some researchers try to understand how 
life might have started. Some try to elucidate how the whole process works. Some try to use the 
properties of nucleic acids as a tool for various purposes. The continuous effort over more than a 
century explored a lot about the structures and functions of nucleic acids. There is a lot to be 
discovered yet. 
This work began with the design and development of a new class of nucleoside analogue with 
the goal to study their ability to bind nucleic acids. The ongoing research will establish their 
application as therapeutics and as biomolecular tools. Along the way significant effort went into 
preparing these analogues. New methodology was developed to address some of the unanswered 
synthetic problems of nucleoside chemistry.  
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1.1. Nucleic Acids- Discovery and Brief History 
Nucleic acids are considered to be the foundation of every life form on earth. 2-
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) constitute the family, nucleic 
acids. In its simplest state, DNA is an ensemble of nucleic acids, water and salts, and the 
structure of the ensemble is dynamically dependent on all three components, e.g., 
sequence of nucleic acid bases, type and concentration of salts and the level of 
hydration1. DNA is a polynucleotide containing the genetic instructions used in the 
development, functioning and replication of all known living organisms (with the 
exception of RNA viruses). Genes are the DNA segments that carry this genetic 
information. Other DNA sequences have structural purposes, or are involved in 
regulating the use of this genetic information. In the modern era, nucleic acids have 
become an exciting area of research for its diverse applicability in a wide spectrum of 
fields2 such as medicine, biology, chemistry, biotechnology, molecular biology, 
nanotechnology, material science etc.  
In 1869 DNA was first isolated by the Swiss physician Friedrich Miescher. The isolation 
of a phosphorus and nitrogen containing acidic substance that was common to many 
discrete cell types began the study of the substance he named "nuclein"3. Albrecht Kossel 
isolated the non-protein component of nucleic acid and later isolated its five primary 
nucleobases in 18784. The use of dyes capable of staining nuclein, as well as the rod 
shaped structures located in the nucleus of cells during certain stages of cell division led 
Flemming to conclude that “inheritance may, perhaps, be affected by the physical 
transmission of a particular compound from parent to offspring”. These early discoveries 
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led others to continue their investigations into this substance, which eventually shed light 
on both the structures and functions of nucleic acid polymers.  
Research into nuclein remained steady during the first half of the 19th century. After four 
decades, in 1919, Phoebus Levene identified the base, sugar and phosphate nucleotide 
unit5. He suggested that DNA consisted of a string of nucleotide units linked together 
through the phosphate groups, and resulted in the discovery of pentose carbohydrates 
linked through phosphodiester bonds (Figure 1 .1 ) forming long polymers capable of 
weighing thousands of  
 
Figure 1.1. Single DNA strand illustrating the three major components that make up an 
oligonucleotide- nucleobase, carbohydrate, and phosphodietster linkage along the 
backbone. The phosphates link the nucleosides together through 3’-5’linkages for both 
DNA and RNA. 
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Daltons. In 1927 Nikolai Koltsov proposed that traits would be inherited via a "giant 
hereditary molecule" which would be made up of "two mirror strands that would replicate 
in a semi-conservative fashion using each strand as a template"6. Next year, Frederick 
Griffith discovered that traits of the "smooth" form of the Pneumococcus could be 
transferred to the "rough" form of the same bacteria by mixing killed "smooth" bacteria 
with the live "rough" form7. DNA's role in heredity was confirmed in 1952, when Alfred 
Hershey and Martha Chase showed that DNA is the genetic material of the T2 phage8. 
Chargaff9 discovered a consistent proportionality between adenine (A) and thymine (T) 
as well as cytosine (C) and guanine (G) that supported Gullard’s earlier belief in 
hydrogen bonding interactions between purines (A and G) and pyrimidines (C and T). 
The miss-assignment of the thymine and guanine bases in their enol rather than keto form 
prevented the breakthrough that would soon revolutionize the study of nucleic acids and 
biochemistry. 
To explain a lot of phenomenon it was necessary to confirm the structure of DNA by X-
ray crystallography.  In 1937, William Astbury produced the first X-ray diffraction 
patterns that showed that DNA had a regular structure10. After about 15 years, James D. 
Watson and Francis Crick suggested what is now accepted as the first correct double-
helix model of DNA structure in 1953. Their key piece of evidence came from a crystal 
structure obtained from their collaborators Wilkins and Franklin (Figure 1.2)11. The X-
ray diffraction pattern implied a helix with two periodicities along the major axis, a major 
one with a length of 3.4 Å and a secondary one of 34 Å.   
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Figure 1.2. Photograph of the X-ray diffraction pattern observed by Wilkins and 
Franklin.  
 
1.2. Structure of DNA and RNA 
Structurally the building blocks of single strand DNA (Figure 1.1) and RNA are 
nucleotides. Nucleotides have three major components - nucleobase, sugar moiety, and 
the phosphodiester linkage. Nucleobase tethered to the sugar is called nucleoside. 
Nucleosides with a phosphate at C5’ are the unit of a nucleic acid polymer- nucleotide. 
The difference between DNA and RNA lies in the fact that the latter has a 2’-hydroxyl in 
the sugar moiety instead of hydrogen. 
Nucleobases 
 
Figure 1.3. Structure and conventional numbering nomenclature of nucleobases (Top- 
Purine: adenine and guanine respectively; Bottom- Pyrimidine: thymine, uracil and 
cytosine respectively). 
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There are two classes of natural nucleobases- single ringed pyrimidines and double 
ringed purines. Thymine, cytosine and uracil constitute the pyrimidines whereas adenine 
and guanine constitutes the purines. The structure and the conventional numbering 
pattern have been summarized in Figure 1.3. In DNA, all these nucleobases exist except 
uracil. On the other hand in RNA, all the nucleobases exist except thymine.  
Sugar or the Carbohydrate Moiety  
The ribose portion of nucleic acids (DNA and RNA) forms the scaffold that connects the 
nucleobases to the phosphodiester backbone linking the polymer together. The sugar unit 
for the RNA is the D-ribofuranosyl sugar whereas the DNA lacks the 2’ hydroxyl of that 
sugar. Nucleobases are coupled to the sugar through glycosidic bonds between the Cl’ 
position on the sugar and the N9 or N1 positions of purines and pyrimidines respectively. 
The nucleobases can rotate about the glycosidic bonds; however, they are predominately 
found in two major regions called syn- and anti-positions (Figures 1.4), with the anti-
position being favorable due to reduced steric clash between the sugar and nucleobase. 
Nevertheless, examples of both these conformations are known in nature.  
 
Figure 1.4. Rotation about the glycosidic bond. The anti-conformation allows the 
standard Watson-Crick hydrogen bonding whereas syn-conformation can be favored 
under certain conditions, like a bulky substituent at C8 of purine or C5 of pyrimidines or 
under high salt concentration or lower hydration.  
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The sugar or the carbohydrate moiety can exist in a number of different conformations. 
The two most common conformations or sugar pucker are C2’-endo and C3’-endo 
(Figure 1.5). The sugar conformation adopted in B-form DNA, the most common form, 
and RNA are C2’-endo and C3’-endo respectively. 
 
Figure 1.5. Most common sugar pucker- C2’-endo and C3’-endo. 
 
Phosphate Backbone 
The final component of a nucleic acid polymer is the phosphodiester linkage connecting 
the sugar moieties and forming the biopolymer. (Figure 1.1) These negatively charged 
phosphates12 impart a chemical stability toward hydrolysis that is thought to be critical 
for genome stability. 
It is important to emphasize that there are many advantages of having a phosphate group 
as a linker rather than other alternatives like esters, amides, citric esters, arsenic esters, 
silicic esters etc. There is a wide range of reasons why these alternatives have 
limitations13. The limitations include, not limited to, higher hydrolytic rates, being 
neutral, toxicity, specificity issues etc. The existence of a genetic material such as DNA 
requires a scaffold for a connecting link that is at least divalent. It needs to be charged in 
order to be confined within the membrane, and therefore the linking unit should have a 
third, ionizable group. In order to make it hydrolytically stable the charge should be 
negative and should be physically close to the ester groups. All of these conditions are 
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met by phosphoric acid, and no suitable alternative is obvious. Another reason why 
nature prefers phosphate esters is its unique balance of reactivity and stability. 
Nevertheless, a biochemical system must not be so stable that it cannot be taken apart.  
DNA must be metabolized. Understanding the mechanisms of enzyme action is among 
the important challenges for physical organic chemistry today, but the fact that enzymes 
exist that can hydrolyze the diesters of phosphoric acid is sufficient to suggest that it is 
kinetically stable and thermodynamically labile.  
1.3. Different forms of DNA 
The three most common forms of DNA are below in (Figure 1.5): A-form, B-form, and 
Z-form. Under physiological conditions, the B-form is the most prevalent form of DNA.  
 
Figure 1.5. Structures of of A-DNA, B-DNA and Z-DNA (left to right)14. Top: Side 
view, Botton: Top view. 
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Before describing the features of these helices, it is important to introduce a few 
parameters that are important. 
Structural Parameters 
Base tilt is rotation about the short axis through the base pair. Roll is the rotation of the 
base pair about the long axis normal to the helical axis. Propeller twist is the rotation of 
one base with respect to the other in the same base pair. Rise is the distance between each 
base pair along the helical axis. Helical twist is the rotation around the helical axis. 
Helical pitch is the distance per helical repeat. Slide and shift are displacements of the 
base pair in the plane normal to the helical axis (Figures 1.6. and 1.7.).  
 
Figure 1.6. Some of the structural parameters used with nucleic acids. 
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Figure 1.7. Left: Illustration of Rise, Roll, Slide Twist, Tilt and Shift. Right: Closer look 
at Propeller twist and Tilt. 
 
Sugar Pucker 
It has been discussed in section 1.2.  
Base Pair (bp) 
The two base pairs and the hydrogen bond involved in the pairs (Figure 1.8).  
 
Figure 1.8. Two base pairs observed in DNA duplex. 
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Grooves 
As the two strands of DNA duplex are not directly opposite each other, the grooves are 
unequally sized. The major groove occurs where the backbones are far apart, the minor 
groove occurs where they are close together (Figure 1.9). The grooves twist around the 
molecule on opposite sides. The narrowness of the minor groove means that the edges of 
the bases are more accessible in the major groove. As a result, proteins can bind to 
specific sequences in double-stranded DNA usually by making contacts to the sides of 
the bases exposed in the major groove15.  
 
Figure 1.9. Illustration of Major and Minor grooves in a DNA duplex. 
 
In all forms the base pairing of nucleotides requires that the bases be nearly perpendicular 
to the major axis of the duplex, and each base pair must be nearly linear and coplanar. 
With these parameters it is possible to describe the structural features and differences 
between A, B, and Z-form DNA.  
B-form is the most common structure of DNA duplex and it is right-handed helix. B-form 
DNA is narrower and elongated than A-form due to a C2′-endo sugar puckering placing 
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the backbone hydroxyls 7.0 Å apart. This form of helical DNA places the base pairs at 
the center of the vertical axis, resulting in more equally sized major and minor grooves. 
The base pairs are nearly perpendicular to the vertical axis of the helix with a small 
inclination of -1.2o. B-form DNA is less distorted and more symmetrical than both A- or 
Z-form helices. Some of the other features have been summarized in Table 1.1. 
A-form is a right-handed helix with the widest diameter and smallest rise per base pair of 
any form, both attributed to the sugar pucker. The C3′-endo sugar pucker places the 3′- 
and 5′- hydroxyls within 5.9 Å of one another, leading to its small rise and wide diameter. 
The large diameter places the base pairs off-center of the vertical axis, resulting in 
exaggerated major and diminished minor grooves. The major groove is very deep, while 
the minor groove is extremely shallow. Base pairs in an A-form conformation are on a 
severe incline of +19o. Other important features and a comparison between the different 
form of DNA have been summarized in Table 1.1. 
Z-form has remarkable differences compared to the other two forms. They are the most 
distorted form of DNA within cellular conditions. Although it is thought that it relieves 
supercoiling of DNA while transcription occurs16, but the actual role in nature is still 
unclear. Z-DNA has left-handed helicity which is generally disfavored. Alternating 
poly(dGC) sequences in the presence of high salt can encourage B- to Z-form transitions. 
Interestingly, the sugar pucker in these alternating poly(dGC) sequences is C2′-endo for 
dC residues and C2′-exo for dG residues. Z-form DNA is the only naturally occurring 
helix with syn conformation of dG residues. These features cause the repeating unit of Z-
form to be 2 base pairs, as opposed to a repeating unit of 1 base pair for A- and B-forms. 
It has the narrowest diameter of all 3 forms and a severe degree of rotation per base pair 
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(60o versus ~35o for A- and B- forms). The Z-DNA conformation has been difficult to 
study because it does not exist as a stable feature of the double helix. Instead, it is a 
transient structure that can be induced by binding with certain proteins that reverts back 
to B-form afterwards17. 
Table 1.1. Features of A, B and Z-DNA18. 
 A B Z 
Helicity Right-handed Right-handed Left-handed 
Repeating Unit 1 bp 1 bp 2 bp 
Rotation/bp 33.6° 35.9° 60°/2 
Average bp/turn 10.7 10.5 12 
Conformation about Glycosidic 
Bond 
Anti Anti C: anti, G: syn 
Sugar pucker C3'-endo C2'-endo C: C2'-endo, G: C2'-exo 
Diameter 26Å 20Å 18Å 
Rise/bp 2.3 Å 3.4 Å 3.8 Å 
Pitch 24.6 Å 35.7 Å 45.6 Å 
Tilt 19° -1.2° -9° 
Propeller twist 18° 16° 0° 
 
Factors Determining the Structure of DNA Duplex 
There are a lot of factors involved to determine the overall dynamically favored structure 
of DNA duplex. It is to be emphasized here that the forms of DNA are not static 
structures. It is, rather, an equilibrium of various states of dynamic structures. The major 
factors that are responsible include base-pairing, π-stacking, steric effects, charge-charge 
repulsion, hydration, salt concentration, super-coiling, metal binding, temperature, 
interaction with external entities like proteins, the DNA sequence etc. The issues get even 
more complicated because DNA can bend, compress, stretch, and unwind differently 
under the influence of these factors.  
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Base-pairing19: Base-pair interaction is in the plane of the bases (horizontal) due to 
hydrogen bonding. Adenosine base pairs with thymidine through two hydrogen bonds, 
whereas guanosine base pairs with cytosine using three hydrogen bonds (Figure 1.3.3.1.). 
As a proof that this actually contributes to the stabilization of DNA duplex, it has been 
observed in numerous instances that sequences rich in G-C base pairs have been shown to 
be more stable than sequences rich in A-T base pairs because of the presence of a third 
hydrogen bond. Another indication that hydrogen bonding affects duplex stability is that 
longer sequences of polynucleotides are more stable than shorter sequences due to the 
presence of additional hydrogen bonds.  
Base stacking19: Base stacking interactions are perpendicular to base planes stabilized 
mainly by -interaction, London dispersion forces and hydrophobic effects. At its core 
of DNA, there is a series of aromatic rings (the nucleobases) stacked on each other. It is 
believed that the - interactions results from interactions of the electron cloud above 
and below the plane of the molecule. These effects give a net effect that stabilizes the 
duplex and keeps the structure intact. The hydrophobic effect certainly plays a role in the 
aggregation and stacking of oligonucleotide heterocycles in addition to the contributions 
from π-π interactions. 
 
Charge-charge repulsion: The backbone of the DNA is a negatively charged 
phosphodiester linkage. The proximity of negatively charged backbones results in 
charge-charge repulsion. The concentration of cations within the environment is directly 
proportional to the stability of the duplex. Increasing the concentration of salt within 
solution has been shown to give higher melting temperatures20. These cations have been 
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shown to closely associate with the negative backbone, as well as in regions where the 
two strands are within their closest proximities21. 
 
DNA Hydration: Hydration of DNA is a special feature of the minor grooves. It is an 
important factor in determining the duplex structure (A-form or B-form) and contributes 
to the overall stability of the duplex by adding additional hydrogen bonding interactions 
with exposed functional groups on the exterior of the duplex. It is especially important 
for the stabilization of minor groove of A-tract DNA. The minor groove of A‐tract DNA 
provides a unique chemical environment. The polarity and electronegative potential are 
high. The floor and walls of the groove are lined with hydrogen bond acceptors but are 
devoid of hydrogen bond donors22. A stabilizing two‐tier ‘spine of hydration’ was 
postulated from medium and low resolution X‐ray diffraction data23. The primary shell or 
spine of hydration is defined as the nearest layer to the duplex engaged in direct 
interactions with functional groups on the surface of the duplex and often with other 
waters in the primary shell. The secondary shell is the next layer of water engaged with 
the first, and so on.  
 
The supercoiling and bending of DNA becomes vitally important in the cellular 
processing and storage of its genetic material. Moreover, a great deal of packaging and 
compression is necessary. DNA is wound tightly around spool-like proteins known as 
histones, which are then further packaged as chromatin and compacted into 
chromosomes. 
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1.4. Nucleoside Analogues 
A plethora of examples of nucleosides are known that differ to various extents from the 
common canonical nucleosides. These are referred to as nucleoside analogues. The 
variation may be  simple as a replacement of an atom by another, for example replacing 
the sugar ring oxygen by carbon or sulfur, or change in the bond order, for example 
connecting the C2’ and C3’ by a double bond. The modification can be fairly 
complicated, for example connecting the C2’-oxygen and the C4’ by a methylene group 
of the ribonucleoside or extending the aromaticity of nucleobases or tethering different 
functionally important groups at specific positions of the nucleobases. Some of the 
examples have been discussed in this section.  
Some of examples of these analogues exist naturally in tRNA (Figure 1.10). Inspired 
from nature, chemists have also developed wide range of nucleoside analogues altering 
the nucleobase, sugar moiety, the backbone or a combination of all three of them. 
 
Figure 1.10. Structures of a few nucleoside analogues present in t-RNA. 
1.4.1. Nucleobase Modification 
In order to study the effect of modified nucleobases on Watson-Crick(W-C) base pairing 
and in part, to expand the genetic code, Kool and co-workers synthesized a range of 
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expanded nucleobases (Figures 1.11 and 1.12)24. They designated the three classes of 
these nucleobases: xDNA (expanded DNA)25, yDNA(wide DNA)26 and yyDNA( double 
wide DNA)27.  
They found that self-complementary xDNA 10-mers, in which each of the nucleobases 
was ‘horizontally’ expanded by the width of a phenyl right (2.4 Å), still formed a 
standard B-DNA duplex. In fact, the helical right-handedness, deoxysugar and glycosidic 
confirmations were identical to that of B-DNA.  These results showed that W-C base 
pairing is not limited by the diameter of the helix. CD and Tm analysis also showed that 
xDNA, with its increased helical diameter, formed a thermodynamically stable helix. 
   
 Figure 111.. Examples of x-modified 
modified nucleosides. 
 
 
 
yDNA which differs from xDNA only in the direction of expansion,  also showed 
remarkable helix stability compared to DNA controls.  A naturally occurring octameric 
sequence of DNA displayed greater duplex stability with a complementary sequence 
composed entirely of yDNA compared to the natural complementary DNA strand. 
yyDNA (Figure 1.12) , the set of fluorescent naptho-homologated DNA nucleobases, 
designed to test the true limits of W-C base pairing also formed stable helices. 
Observations such as these have led to increasingly accurate models of the structure of 
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DNA and the nature of Watson-Crick base pairing and have made unnatural nucleic acids 
an indispensable tool in the scientific field. 
 
 
Figure 1.12. Examples of  yy- 
modified modified nucleosides. 
 
 
Other fluorescent nucleobase analogs have proven to be an indispensable tool in 
biochemistry and molecular biology. Greco and Tor have synthesized a fluorescent 
pyrimidine nucleobase which when paired with a DNA abasic site, displays significant 
fluorescence (Figure 1.13)28.  
  
Figure 1.13. Fluorescent Pyrimidine Analog.  
 
 
In addition those that recognize complementary single stranded RNA and DNA, 
nucleoside analogs that target double stranded DNA (dsDNA) have been the subject of 
much attention.  Using phophoramidites prepared from monomers including and similar 
to the molecule shown in Figure 1.14, Gold and co-workers have been able to synthesize 
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these triplex-forming oligonucleotides (TFOs) that specifically recognize T:A, A:T,G:C 
or C:G base-pairs via Hoogsteen base pairing29. These TFOs potentially allow for control 
of gene expression at the transcriptional level by binding to sequence-specific regions on 
the DNA duplex. 
  
Figure 1.14. Gold’s nucleoside analog designed target A:T 
base pair.  
 
 
 
1.4.2. Sugar Modification 
Manipulation of the ribose or deoxyribose portion of the nucleic acid also confers 
oligonucleotide stability towards nuclease degradation. Additionally, some of the truly 
ingenious modifications that are described below have allowed for improved plasmid 
DNA functionality30, DNA triplex formation31 and nucleic acid – protein binding32. 
A common modification is the substitution of the ring oxygen with sulfur. Haraguchi and 
co-workers recently devised the synthesis of the 4’-thionucleoside (Figure 1.15)33. When 
incorporated into an oligonucleotide, this derivative showed marked resistance to 3’-
exonuclease cleavage. Interestingly, the 4’-thioDNA:4’-thioDNA homoduplex adopted 
A-form characteristics under physiological conditions. The affinity of this 
oligonucleotide for a complementary RNA sequence was not tested; however, the RNA-
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like features of the homoduplex suggest an increased affinity for the complementary 
RNA sequence compared to the native oligonucleotide.  
A series of carbocylic (deoxy)ribose nucleoside derivates have also been synthesized.  
These nucleosides have had the ring oxygen replaced by a carbon atom. Carell and co-
workers exploited the inability of these carbocylic nucleosides to anomerize in order to 
study DNA lesions34. Previously, a rigorous study of such lesions was not possible since 
base-pairing effects could not be quantified due to the rapid inter-conversion of the α and 
β confirmations. Carbocylic nucleosides have also been synthesized to act as agonists for 
A3 adenosine receptors which have critical cardiac and immunological functions35. 
 
Figure 1.15. Left- Haraguchi’s 4’-thionucleoside. Right- Carell’s carbocylic guanine. 
 
Attempts to completely replace the ribose structure have also been made. In an 
experiment that test the limits of Watson-Crick base pairing, Meggers and co-workers 
have synthesized a nucleoside derivative that completely replaces the ribose sugar with a 
3-carbon glycol framework (Figure 1.16)36. When incorporated into oligonucleotides, 
these simplified nucleic acids form stable duplexes - suggesting a possible predecessor to 
RNA as the genetic material for early life.  
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       Figure 1.16. Megger’s glycol-based oligonucleotide. 
 
 
Another class of modified nucleosides is rigidified nucleosides. In these classes of 
molecules the nucleosides are rigidified by restricting the sugar or the base with respect 
to the sugar. We will discuss about it in Chapter 3.  
 
1.4.3. Backbone Modification 
While modification of the nucleobase has allowed for the exploration of the limits of W-
C base pairing, the expansion of the genetic code and the ability to control gene 
expression at the transcriptional level, the susceptibility of unnatural oligonucleotides to 
enzymatic degradation is linked more closely to the nucleic acid backbone. A common 
modification of the phosphodiester bridge is the replacement of a non-bridging oxygen 
with a sulfur atom. Not only does this modification increase stability to endogenous 
enzymes, it enhances protein binding, reduces clearance and improves bioavailability. 
Stec and co-workers have synthesized a related phosphoroselenoate linker (Figure 1.17) 
and the Rozners lab has prepared oligoribonucleotides with amide linkages37. 
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Figure 1.17. Stec’s phosphoroselenoate linker. 
 
 
Another important modification is to replace the negatively charged phosphodiester 
backbone by peptide linkage. The widely research polymers in this category are Peptide 
Nucleic Acids (PNA). We will discuss about it in the next section. 
 
1.5. Peptide Nucleic Acid (PNA) 
PNA (Figure 1.18) was originally designed as a ligand for the recognition of double 
stranded DNA38. The concept was to mimic an oligonucleotide binding to double 
stranded DNA via Hoogsteen base pairing in the major groove39. Thus the nucleobases of 
DNA were retained, but the deoxyribose phosphodiester backbone of DNA was replaced 
by a pseudo-peptide backbone. In theory a neutral (peptide) backbone should improve the 
triplex binding capability of the ligand, and it is believed that the pseudo-peptide 
backbone was a good chemical scaffold that would allow us to design recognition 
moieties that went beyond homopurine targets. There has been a wide variety of 
substitutions in the backbone, that we will discuss about later.  
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Figure 1.18. Illustration of a 
PNA-RNA duplex with 
possible substitutions in the 
backbone of PNA. 
 
 
 
 
 
 
PNAs as we know them today have a backbone made from repeating N-(2-
aminoethyl)glycine units linked by peptide bonds40. The different bases (purines and 
pyrimidines) are joined to the backbone by methylene carbonyl linkages. They are 
depicted as peptides from the N terminus to the C terminus, corresponding to the 5’ to 3’ 
direction as in DNA because all intramolecular distances and the configuration of the 
nucleobases are similar to those occurs between PNA and DNA or RNA sequences by 
hydrogen bonding (Figure 1.18). The uncharged nature of PNA is responsible for the 
better thermal stability of PNA/DNA duplexes compared with their DNA/DNA 
equivalents. 
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1.5.1. Properties of PNA 
 Modes of Binding 
It is important to emphasize the directionality of PNA while binding to DNA (Figure 
1.19). 
 
Figure 1.19. Schematic representation of a PNA-DNA duplex in the antiparallel mode 
(3’-end of the DNA facing the amino-terminal of the PNA), a 2PNA/DNA triplex in the 
preferred binding mode with antiparallel Watson-Crick strand and parallel Hoogsteen 
strand a linker of a bis-PNA is indicated), and a triplex strand invasion complex using a 
bis-PNA. PNAs are shown in red. Watson-Crick hydrogen bonds are indicated by ‘-‘, 
while Hoogsteen Crick hydrogen bonds are indicated by ‘:‘.  
There are four different binding modes on targeting double-stranded DNA with PNAs 
have been described (Figure 1.20). These include conventional triplex binding in the 
major groove of the DNA double helix41 (Figure 1.20 A) and triplex invasion in which 
two PNA oligomers invade and open this DNA double helix through formation of an 
internal PNA-DNA-PNA Watson-Crick-Hoogsteen triplex40 (Figure 1.20 B and C). 
Duplex invasion through an internal PNA-DNA Watson- Crick duplex42 (Figure 1.20 C) 
has also been observed under certain conditions, and if special modified pseudo-
complementary bases, such as the diaminopurine-thiouracil base pair, are employed in 
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the PNA oligomers, binding to the target by double duplex invasion is possible (Figure 
1.20 D).  
 
Figure 1.20. Illustration of the binding modes on targeting DNA duplex by PNA. The 
ladder represents the DNA duplex and the PNA oligomer is bolded. 
 
Structure of PNA Complexes 
Three-dimensional molecular structures have been determined for the basic PNA 
complexes. The structures of a 9-mer PNA2-DNA triplex
43 and a hexamer PNA-PNA 
duplex44 were determined by X-ray crystallography; while the structures of a 6-mer PNA-
RNA45 and an 8-mer PNA-DNA46 duplex were determined by NMR. Following are the 
observations about the structure of PNA hybrids: 
 The binding of PNA to single stranded DNA or RNA allows the backbone of the 
nucleic acid partner to retain close to its ‘natural’ conformation. The RNA in the 
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PNA-RNA duplex is close to an A-form with C3’-endo sugar puckering; whereas 
the DNA in the PNA-DNA duplex is closer to B-form with C2’-endo sugar 
puckering. 
 The two duplexes also show a tendency towards a larger pitch than the usual 10- 
11 base pairs seen in nucleic acid duplexes. 
 Both the PNA2-DNA triplex and especially the PNA-PNA duplex both show a 
very wide (26 and 28 Å, respectively) and a very large pitched helix (16 and 18 
bases for the triplex and duplex respectively) 
Thermal Stability of PNA hybrid complexes 
One of the most important aspects of the PNA hybrid complexes is the higher thermal 
stability of PNA/DNA and PNA/RNA duplexes compared with DNA/DNA and 
DNA/RNA duplexes47. This stronger binding is attributed to the lack of charge repulsion 
between the neutral PNA strand and the DNA or RNA strand. As a general rule, Tm of a 
PNA/DNA duplex is 1 ◦C higher per base pair than Tm of the corresponding DNA/DNA 
duplex (in 100 mmol/dm3 NaCl). Some of the following data show the greater stability 
(reflected in the higher Tm values) of PNA/DNA or PNA/RNA duplexes
48: a) 15-mer 
PNA/DNA, Tm = 69 ◦C; b) 15-mer DNA/DNA, Tm = 54 ◦C; c) 15-mer PNA/RNA, Tm = 
72 ◦C; d) 15-mer DNA/RNA, Tm = 50 ◦C. 
Effect of Salt Concentration on Binding 
The Tm values of PNA/DNA duplexes are practically independent of salt concentration. 
This is striking difference to that of the DNA/DNA duplexes, which are highly dependent 
on ionic strength. At low ionic strength, PNA can bind to a target sequence at 
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temperatures where DNA hybridization is disfavored. Hybridization of PNA is also fairly 
independent of the concentration of magnesium ion40.  
Binding Specificity 
PNA also shows greater specificity in binding to complementary DNA49. A PNA/DNA 
mismatch is more destabilizing than a mismatch in a DNA/DNA duplex. A single 
mismatch in mixed PNA/DNA 15-mers lowers Tm by 8–20 ◦C (15◦C on average). In the 
corresponding DNA/DNA duplexes a single mismatch lowers Tm by 4–16 ◦C (11◦C on 
average). 
Resistance to nucleases and proteases 
PNAs with their peptide backbone bearing purine and pyrimidine bases are not molecular 
species that are easily recognizable by either nucleases or proteases50. Therefore the 
lifetime of these compounds is extended both in vivo and in vitro. 
PNA Insolubility in Water 
Being charge-neutral biopolymers, PNA have poor water solubility compared with DNA 
or RNA. PNA molecules have a tendency to aggregate to a degree that is dependent on 
the ratio of purine to pyrimidine, the sequence and length of the oligomer4247. Some 
recent modifications, including the incorporation of positively charged lysine residues 
(carboxyl-terminal or backbone modification in place of glycine), have shown 
improvements in solubility. 
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1.5.2. Modification of PNA Backbone 
There have been two major directions to modify the backbone to enhance its binding 
properties and solubility in water. First, change the length of the backbone and the length 
between the backbone and the base. Second, substitutions at the α-position of the glycine 
moiety. Extensions in any of the three possible directions51 (entry 2-4, Table 1.2) are not 
desirable, and the restricted flexibility imposed by the secondary amido-group also seems 
necessary since reduction of this to a tertiary amine (entry 5, Table 1.2) is deleterious to 
the hybridization potency52. Also, an isomerization of the backbone to the ‘retro-inverso’ 
structure (entry 6, Table 1.2) which essentially moves a methylene group from the ‘ethyl’ 
to the ‘glycine’ moiety results in PNAs of low hybridization efficiency. 
 
Table 1.2. Effects on thermal stability (ΔTm ᵒC) for structurally modified PNA in which 
T-monomers when incorporated into the oligomer sequence H-GTA GAT CAC T-NH2
53
. 
On the other hand, substitutions at α-position of the glycine unit in the backbone show 
some promise. Table 1.3 summarizes some the results obtained by this strategy. It is 
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evident that PNA backbones based on other natural amino acids than glycine result in fair 
to good DNA mimicking properties with some variations amongst the different amino 
acids54. By using such PNA monomers, various chemical scaffolds can be introduced into 
the backbone and the physical properties of the PNAs, such as solubility, hydrophobicity, 
ionic properties etc. can be modulated. Especially it was shown that PNAs containing a 
few lysine-monomers (entry 14 and 15, Table 1.3) have increased aqueous solubility. 
 
Table 1.3. Effects on thermal stability (ΔTm ᵒC) for the PNA sequence H-GTA GAT CAC 
T-NH2 incorporating three chiral monomers as compared to an unmodified PNA
53. 
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1.6. Factors Determining the Modified Nucleic Acids Binding Properties   
One of the primary goals to develop the modified nucleic acids is to form stronger 
binding to the complementary DNA or RNA. In principle it can be achieved either by 
increasing the enthalpy and/or decreasing the entropy of duplexation. Enthalpic 
stabilization of duplexation can be addressed by substituting the negatively charged 
phosphate groups in natural oligonucleotides with charge-neutral nucleoside linking 
groups such as phosphotriester55, methyl phosphonate56, phosphoramidate57, sulfonate58, 
and acetal groups59. Substitution of 2,6-diaminopurine for adenine as the nucleobase in 
DNA oligomers60 stands as an example of enhanced enthalpic stabilization of the 
resulting duplexes due to an additional H-bond in the diaminopurine-thymine base pair 
with respect to the parent adenine-thymine base pair. We discussed some other examples 
in section 1.5. Entropic stabilization can be achieved by proper preorganization. 
Nucleosides have been designed and synthesized to confer, as constituents of an 
oligonucleotide chain, a higher degree of preorganization of a single strand for duplex 
formation with respect to natural DNA, thus leading to an entropic advantage for the 
pairing process. 
The concept of “preorganization” was first introduced by Cram in the analysis and design 
of small organic guest-host complexes61. It was found that entropy factor disfavors the 
formation of such guest-host complexes for two reasons: i) three degrees of translational 
and rotational entropy are lost in forming a complex from two separate molecules, ii) if 
either of the separate molecules has free internal bond rotations, then the “freezing out” 
of all such rotations on forming the complex is also entropically unfavorable62. For 
molecular recognition, the first can’t be avoided because the phenomenon fundamentally 
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needs this to happen. However, the second factor can be addressed by the tuning, 
designing and testing. If a host molecule or ligand is constructed so as to be rigidly held 
in the binding conformation prior to complexation, then little or no entropic cost due to 
fixing bond rotations will be necessary in binding44. In other words, a flexible molecule 
can be preorganized in the synthesis for optimum binding. It is to be emphasized here that 
the preorganization should not hold the molecule rigidly in the wrong conformation63.  
 
Figure 1.21. Competitive thermodynamic factors favoring the complex formation. 
 
The concept of preorganization holds true for nucleic acid duplex formation, especially 
sequence specific recognition of a single-stranded nucleic acid by another 
oligonucleotide. A single-stranded nucleic acid is quite flexible, with rotation of the 
nucleobase with respect to the sugar moiety about the glycosydic bond and about five 
freely rotating bonds per phosphate. Helix formation is therefore highly unfavorable 
entropically and is a spontaneous reaction only because a very favorable enthalpy term 
just compensates (Figure 1.21).  
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1.7. Potential Applications of Modified Oligonucleotides as Therapeutics 
Modified nucleotides have found applications in therapeutics by modulating the gene 
expression. Broadly, an oligonucleotide designed to alter gene expression can act either at 
the level of DNA duplex to inhibit transcription (also known as “the antigene approach”) 
or at the level of m-RNA to inhibit translation (known as “the antisense approach”). The 
overall mechanism has been summarized in Figure 1.22. 
 
Figure 1.22. Conceptual representation of antisense-mediated gene-silencing approaches (R 
represents RNA-induced silencing complex, or RISC). 
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1.7.1. Perturbing Gene Expression at Transcriptional Level (Antigene Approach) 
By hybridizing synthetic oligodeoxynucletides with double-stranded DNA64- These 
hybrids are generally formed within the major groove of the helix, but there are a few 
strategies for hybridization within the minor groove that have also been reported65. In 
either case, a triple-stranded molecule is produced, hence the origin of the term triple-
helix forming oligodeoxynucleotide (TFO) (Figure 1.22 and 1.23). TFOs may act in two 
ways. They may prevent binding of transcription factors to the gene’s promoter and 
therefore inhibit transcription. Alternatively, they may prevent duplex unwinding and, 
therefore, transcription of genes within the triple-helical structure. 
 
Figure 1.23. Triplex Forming Oligonucleotide (TFO) in the Major Groove of DNA 
Duplex. 
 
Use of specific nucleic acid sequences to act as ‘‘decoys’’ for transcription factors66- 
Since transcription factor proteins recognize and bind specific DNA sequences, it is 
possible to synthesize nucleic acids that will effectively compete with the native DNA 
sequences for available transcription factor proteins in vivo. However, in practice this 
approach has limitations. For example, unless single gene transcription factors can be 
identified, it is difficult to conceive how this approach, though potentially effective for 
controlling cell growth, can be made gene specific. 
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1.7.2. Perturbing Gene Expression at Translational Level  
Antisense Approach- In antisense strategy of gene silencing, the oligonucleotide forms a 
stable duplex with the targeted m-RNA and inhibits translation either by blocking the 
binding and assembly of the translational machinery to the m-RNA or cleaves the target 
mRNA by recruitment of RNase H67. Steric blockade of the translation is achieved when 
an antisense oligonucleotide is directed to the 5’-terminus of the target, while RNase H-
mediated cleavage occurs when the antisense oligonucleotide binds to the target strand at 
any site to produce a duplex conformation of a DNA-RNA heteroduplex. This 
heteroduplex motif serves as a recognition element of RNase H recruitment, leading to 
the cleavage of the RNA strand68. Inhibition of translation can also be achieved by small 
interfering RNA (siRNA). siRNAs result when exogenous agents like viruses and 
transposons or endogenous genes introduce long double-stranded RNA (dsRNA triggers 
gene silencing by a process which is widely used nowadays know as RNA interference 
(RNAi) (Figure 1.22). 
1.8. Application of Modified Oligonucleotides as Diagnostic Tool 
Probes for Single Nucleotide Polymorphism (SNP) Detection- SNPs are the DNA 
sequence variations occurring when a single nucleotide in the genome differs between 
members of a species. SNPs may fall within coding sequences of genes, noncoding 
regions that may have regulatory effects, or the regions between the genes. SNPs in the 
coding region may alter the gene product (polypeptide) and cause several ailments. The 
high binding affinity and sequence specificity of modified nucleotides find significant use 
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in diagnostics where they are used as probes in several hybridization-based assays such 
as expression profiling, DNA sequencing, SNP genotyping, and so forth69. 
Probes for RNA Capture- For studying expression level and localization of RNA within 
all types of eukaryotic cells, in situ detection of RNAs by hybridization with 
complementary probes is a powerful technique. The favorable properties of the modified 
oligonucleotides make them a good candidate to be used as probes for RNA detection70.  
Probes for micro-RNA detection (miRNA)- miRNA are small (20-23 nucleotide) 
noncoding RNAs that regulate gene expression by base-pairing to partially 
complementary mRNAs. The detection and characterization of miRNAs have been 
technically challenging because of their small size. Modified oligonucleotides, especially 
DNA chimera with several positions substituted by LNA residues have been used to 
significantly increase detection of low-abundance miRNAs71.  
 
1.9. Applications of PNA 
Apart from its potential use as therapeutics to selective inhibition at the transcriptional 
and translational level (Section 1.7) because of their exceptional binding properties, they 
can be used as biomolecular tools. Some of their applications, not an exhaustive list, are 
mentioned below: 
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PNA Assisted Rare Cleavage72 
 
Figure 1.24. Schematic representation of major steps in PNA Assisted Rare Cleavage. 
It is based on the general “Achilles’ heel” cleavage strategy. This methodology makes it 
possible to convert usual restriction enzyme into infrequent genome cutters. In this 
method (Figure 1.24), a very stable and sequence-specific complex is formed between 
double-stranded genomic DNA and a cationic pyrimidine bis-PNA. Then the sample is 
treated with methylases, the bis-PNA is removed from the DNA and the sample is treated 
with a restriction enzyme. The enzyme recognizes the same sites as methylase and thus 
cannot cleave them. The only exceptions are the very few non-methylated sites, which 
are protected against methylation by the bis-PNA. These rare sites become accessible for 
enzymatic recognition after PNA is removed. As a result, the restriction enzyme cuts the 
genomic DNA into small number of fragments. A pool of numerous combinations of 
various bis-PNAs with different methylation/restriction enzymatic pairs generates a new 
class of genome rare cutters. 
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PNA for Artificial Restriction System 
There are many sequences which are not recognized by the restriction enzymes; in such 
cases, PNAs are designed to have their oligonucleotides complementary to the 
recognition sequences. These PNAs hybridize to the complementary targets on dsDNA 
and loop out the non-complementary DNA sequences73. The single-stranded looped-out 
fragments of DNA are then removed by S1 nuclease, which cleaves single-stranded 
nucleic acids. Therefore PNA can be used as a cutting tool in combination with S1 
nuclease to make an ‘artificial restriction enzyme’ system.  
PCR Clamping74 
This method enhances the specificity of the PCR reaction by targeting the initial step 
involved in non-specific amplification75, i.e., the binding of the primer to a mis-matched 
target sequence. As shown in Figure 1, the method operates by competition for a common 
target site between a PNA (complementary to the wild-type target sequence) and one of 
the PCR primers (complementary to the mutant target sequence), or vice versa. When the 
template contains the wild-type sequence, PNA binding will dominate over primer 
binding due to the higher affinity of the matched PNA for the target site. As PNA cannot 
be extended by the Taq-polymerase the effect of this binding is that the amplification 
reaction is impaired. When the mutant sequence is present, PCR primer binding will 
dominate over PNA binding with the resulting generation of amplicons (Figure 1.25). 
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Figure 1.25. Schematic illustration of PCR Clamping. Left- Steps; Right-Typical PCR 
Cycle. 
Oligonucleotide/PNA-assisted Affinity Capture (OPAC)76 
It is a method of sequence-specific isolation and purification of intact double-stranded 
DNA (dsDNA). The protocol involves three steps. First, two cationic bis-PNAs locally 
pry the DNA duplex apart at a predetermined site. Then, the exposed DNA single strand 
is targeted by a complementary biotinylated ODN to selectively form a stable PD-loop 
complex. Finally, the capture of dsDNA is performed using streptavidin covered 
magnetic beads. In essence, the methodology is based on selective tagging of a DNA 
duplex by biotinylated oligodeoxyribonucleotide through formation of a so-called PD-
loop by the aid of a pair of PNA “openers (Figure1.26).  
 
 
 
Figure 1.26. Schematic illustration of steps 
involved in OPAC methodology. 
 
39 
 
1.10. Specific Examples of Modified Nucleosides Which Have Medicinal 
Applications 
Some modified nucleosides are already approved by the FDA for medicinal applications 
whereas others are under investigation for their potentiality as drugs. A discussion of a 
few examples can be found below. 
Cladribine 
As a purine analogue, it is a synthetic anti-cancer agent that also 
suppresses the immune system. Chemically, it mimics the nucleoside 
adenosine and inhibits the enzyme adenosine deaminase, which 
interferes with the cell's ability to process DNA. It is easily destroyed by 
normal cells except for blood cells, with the result that it produces relatively few side 
effects and results in very little non-target cell loss. It is approved for the treatment of 
symptomatic hairy cell leukemia77. 
Tubercidin 
It is a toxic adenosine analogue with antiviral, anti-trypanosomal, and 
antifungal functions. It inhibits multiple metabolic processes which 
include: RNA processing, nucleic acid synthesis, protein synthesis, and 
methylation of tRNA through intracellular incorporation into nucleic 
acids. It also acts as a plant antifungal, inhibits mammalian SAH hydrolase (SAHH), and 
blocks purine biosynthesis in Candida famata. And many others have been developed by 
chemists with specific goals in mind78.  
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Sinefungin 
Sinefungin is a DNA methyltransferase inhibitor and an analog 
of S-adenosyl-L-methionine (SAM) as indicated by previous 
studies. In studies investigating cytosine deamination by DNA 
methyltransferase, it was noted that the presence of Sinefungin 
increased the rate of deamination 103 fold in the presence of its analog SAM, and 104 in 
the absence of SAM. This may suggest that Sinefungin could be useful as a test 
compound in antiviral, anticancer, antiparasitic and antifungal applications. Additional 
studies indicate that Sinefungin was able to inhibit RNA synthesis in a vaccinia virion 
preparation79. 
5-Azacytidine 
It is a potent growth inhibitor and cytotoxic agent and a potent DNA 
methyltransferase inhibitor. It causes DNA demethylation or hemi-
demethylation, creating openings that allow transcription factors to bind 
to DNA and reactivate tumor suppressor genes. It has also recently been 
shown to increase reprogramming efficiency of stem cells 10-fold80. 
Significant other examples 
Chain terminators, such as Zidovudine or Zalcitabine, lack the 3′-hydroxyl necessary for 
addition of sequential nucleosides during replication. Other modifications include those 
seen in Entecavir and Cytarabine. Entecavir has been shown to block the active site of 
viral DNA polymerase.  
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Cytaribine is used as a chemotherapeutic, but works in the same principal by blocking 
DNA and RNA polymerases in rapidly dividing cells. 
1.11. Scope of the Research 
McLaughlin’s group focuses primarily on the chemical modification of nucleosides 
followed by their incorporation in the nucleic acid strand to study their biophysical and 
biochemical properties. Enzymatic incorporation of the triphosphates of these modified 
nucleosides provides another direction for investigation. As we have discussed, 
structurally a nucleic acid strand has three different moieties- the nucleobase, the sugar 
and the phosphodiester backbone (Figure 1.1). Our group develops novel nucleosides by 
modifying some combination of the three. One of the projects focuses on restricting the 
free rotation of the nucleobase about the glycosidic bond to the anti-conformation. This is 
achieved by tethering the C8 of the purine or the C6 of the pyrimidine with the C5’ of the 
sugar. Another major project is to perform minor groove modifications. These are 
performed by introducing different substituents at the C3 position of 3-deaza-purines. 
These modifications provide tools to study the minor groove, including, but not limited 
to, the study of the role the spine of hydration plays in the stability of DNA duplexes.  
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One of the strategies to prepare these modified nucleosides is to employ glycosylation 
methodology to couple the sugar with the nucleobase component. Previous reported 
procedures did not afford the desired results, in terms of regio- and stero-selectivity of the 
glycosylation81. This inspired us to develop methodology to perform this step more 
efficiently. It is not affordable to carry out glycosylations that yield only 25-40% of the 
desired β-N9 product, or sometime even lower overall yield, considering the fact that it 
takes 8-10 difficult steps to synthesize these modified bases. Glycosylation reactions via 
sodium salt method have a number of issues. In my first project, I have tried to address 
some of these issues. Previous research in our lab used tetramethylsuccinic anhydride as a 
directing/protecting group in purine glycosylations82. This methodology proved that a 
cyclic diimide with sufficient steric bulk can function as a directing/protecting group. 
With that observation confirmed, we sought to address whether increasing the steric bulk 
at the sites of the methyl groups would further enhance the directing ability of substituted 
succinimide derivatives. Further investigation resulted in the development of bicyclo-
1,1’-dicarboxylic acid cyclic-anhydride as a directing/protecting, which established our 
hypothesis about sterics at C6 position of the purines.  
Glycosylation reactions are not the only method to access the modified nucleosides. In 
my next project, I developed 8, 6’-(S)- and 8, 6’-(R)-cyclo-2’deoxyadenosine (Figure 
1.28 B and C). The inspiration for developing the route to access these epimers came 
from the amazing binding properties of Locked Nucleic Acids (LNA)83 (Figure 1.27 A) 
to native nucleic acids, especially RNAs. The monomers of the LNA is locked in the C3’-
endo sugar conformation due to rigidity in the structure introduced by the tethering C2’-
oxygen and C4’ of the sugar moiety via methylene group. It has been reasoned that due to 
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the rigidity of the monomers, when they are introduced in the nucleic acid strands they 
are pre-organized to form A-type helices. This preorganization is responsible for the high 
binding selectivity and specificity properties.  With that established approach, we asked 
whether we could introduce rigidity in the structure of the nucleoside monomers by 
freezing the free rotation of the nucleobase about the sugar moiety. This has been 
achieved by introducing intra-residue covalent bond between C5’ and C8 of purine or 
C5’ and C6 of pyrimidine in the first generation analogues. In the second generation, the 
same two centers are connected via a methylene group. In my second project, we were 
able to optimize an efficient route to synthesize both the epimers at C5’ position of 8, 5’-
methylene-cyclo-2’-deoxyadenosine (Figure 1.27 B and C). The goal of my second 
project was to develop these modified nucleosides, so that they could be incorporated in a 
DNA strand to study their properties like binding propensity towards other nucleic acid 
strands, especially RNAs etc.  
 
Figure 1.27. (A) Monomer of LNA; (B) and (C) Epimers of  8, 5’-methylene-cyclo-
2’deoxyadenosine. 
 
In my third project, the goal was to investigate whether we could sequence specifically 
recognize DNA duplexes by Janus Wedge format. The Janus-Wedge (Jw) triple helix84 is 
a fundamentally new approach to target a DNA duplex. In this approach, an incoming 
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peptide nucleic acid (PNA) strand inserts itself between the Watson-Crick (W-C) faces of 
the base pairs in a duplex to generate a new (Jw) three-stranded complex (Figure 1.29)85.  
 
Figure 1.28. Concept of Janus Wedge Triplex. 
The bases on the PNA can be designed so that they have two hydrogen bond forming 
faces with correct hydrogen bond forming profile. The first generation J-W complexes 
(Figure 1.29) were based on a single ring format of a pyrimidinone ring (W1) for 
targeting A-T/T-A base pairs86 and a triazinedione (W2) ring for targeting G-C/C-G base 
pairs87. However, specificity was a problem with the first generation bases. In my third 
project, we designed and synthesized second generation Jw residues to achieve the goal 
of specific DNA duplex targeting. These are asymmetric purine-like Jw base monomers 
that are designed to selectively target and discriminate all four W-C base pairs (A-T, T-A, 
C-G and G-C) and form the basis for the development of highly selective duplex DNA 
targeting modules.  
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Figure 1.29. First Generation Janus Wedge Bases.  
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Background 
The advancement of automated, solid-phase synthetic procedures for the synthesis of 
DNA1 and RNA2 has in the last couple of decades led to widespread use of natural and 
modified nucleic acid analogues in chemistry, medicine, biology and many 
interdisciplinary fields. While synthesized DNA strands having the natural structure are 
most widely used as primers, linkers, and probes in molecular biological techniques, 
there are a host of possible modified DNA structures with many new properties which 
offer a host of new possibilities. One of those structures can be achieved by incorporating 
modified nucleoside monomers in the DNA or RNA strands; with modified base, 
modified sugar moieties, or modification involving both base and sugar. 
In literature, it has been well documented that modified nucleoside monomers can be 
chemically synthesized via divergent or convergent approaches or combination of both 
(Scheme 2.1). The example shown illustrates this concept. Step 1 is an example of 
convergent methodology whereas the subsequent steps show the divergent procedure3. 
 
Scheme 2.1: Example of a combination of convergent and divergent approaches3. 
 
The divergent approach4 became popular when the modification of intact nucleosides was 
the first method available for synthesizing 2’,3’-dideoxynucleosides. In fact, the 
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compounds currently approved by the FDA for the treatment of AIDS (AZT 1, ddC 2, ddl 
3; Figure 2.1) were first synthesized using this approach. These routes rely largely, but 
not exclusively, on strategies which involve the deoxygenation of furanonucleosides. The 
main advantage of these approaches is that control of the glycosidic stereochemistry is 
not an issue, i.e., it is either set by nature or can be controlled synthetically via 
anchimeric assistance of an appropriate 2’-substituent. However, they are limited 
primarily by the availability of naturally occurring nucleoside starting materials (e. g., 
thymidine, cytidine, uridine, adenosine, guanosine).  
 
Figure 2.1: Structure of : 1. AZT; 2. ddC, 3. Ddl. 
Alternately, convergent approaches4 to synthesize nucleoside derivatives are more 
versatile than other approaches, since they involve the coupling of a carbohydrate moiety 
(unmodified or modified) with a purine or pyrimidine base (unmodified or modified) via 
a nitrogen glycosylation reaction. Since these approaches enable one to change both the 
base and carbohydrate components of derivative monomers, they represent the preferred 
strategy for preparing substrates for nucleic acid incorporation and their subsequent 
biochemical and bio-physical studies. In practice, however, this only holds true when the 
glycosylation reaction proceeds with a reasonable degree of stereochemical control. The 
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challenges are apparent in the synthesis of purine 2′-deoxynucleosides, because (1) there 
are theoretically four possible products (Scheme 2.2), and (2) the relative ratios are more 
substrate-dependent. There are several methods for purine glycoslyation, and each affords 
good to excellent selectivity for some substrates, but a general method applicable to the 
synthesis of all purine 2′-deoxyribonucleosides remains elusive. Certainly the most 
common method employed with simple heterocycles such as 6-chloropurine 4 is the 
sodium salt method5; the most common sugar employed is 2-deoxy-3,5-di-O-(p-toluoyl)-
α-D-erythro-pentofuranosyl chloride 56. The glycosylation of 4 gives the desired 6 in 
57% yield with 13% β-N7 product 7 and none of the possible α-nucleoside products 
(Scheme 2.2). 
 
Scheme 2.2. The four possible purine coupling products for the reaction of 6-
chloropurine with 2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl chloride. 
2.1. Common Routes to Prepare 2′-deoxyribonucleosides 
For modified ribonucleosides, the issue of α-anomers can be reasonably avoided by the 
neighboring group effect of groups like benzoyl or acetyl groups at the 2’-position 
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(Scheme 2.3)7. It is possible to utilize these ribonucleosides to access modified 2’-
deoxyribonucleosides by removing the 2’-hydroxyl by methodologies like Barton 
deoxygenation.  
 
Scheme 2.3: Neighboring group effect operating in ribonucleoside synthesis. 
Apart from this approach, there are several procedures for the direct access of 2′-
deoxyribonucleosides. Some of them have been summarized below and illustrated in 
Scheme 2.4. 
a) Sodium salt method (Figure 2.4 A): Adenine (8) can be converted to its sodium 
salt with NaH in acetone, which reacts with 5 to form protected 2′-
deoxyadenosine (9) in 48% yield with 8% α-N9 product8. It was observed that the 
sodium salt of 8 has poor solubility in non-polar solvents like DCM or 
dichloroethane resulting in a slow reaction rate, thereby increasing the 
anomerization of 5 and subsequently producing higher amounts of the α-N9 
product. When the reactions were carried out in polar solvents like ACN or DMF, 
the sodium salt of the bases were found to react faster. However, polar solvents 
also facilitate the anomerization of sugar as well, resulting in more α-nucleoside 
product.  
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b) Metal salt method (Figure 2.4 B): One of the first glycosylation methods 
developed for nucleosides was the metal salt procedure in which the purine is 
converted to a heavy metal salt, typically Hg, and reacted directly with the sugar 
Employing this method compound 10 yielded the desired product 11 in a 25% 
yield with 16% α-N9 product9, a remarkable decrease from the 57% yield 
obtained with 4. A serious drawback of this method is the removal of the highly 
toxic heavy metals like Hg after the reaction.  
 
Scheme 2.4: A few approaches to access 2′-deoxyribonucleosides via different 
glycosylation methods. 
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c) Transglycosylation method (Figure 2.4 C): This method (12) takes advantage of 
the fact that nucleoside formation in the presence of a Lewis acid is a reversible 
process. Lewis acids such as HgBr2, TMSClO4 or TMSOTf are effective in 
promoting this type of glycosylation. In the case of 2-deoxyribose sugars 
significant amounts of the α-nucleoside product are usually obtained. 12 reacts 
with the silylated nucleobase 13 to afford 27% 14 and 36% of the corresponding 
α-N9 product10. When 12 reacts with silylated nucleobase 13 in presence of 
TMSOTf, 27% of the desired 14 and 36% of the corresponding α-N9 product 
were reported10.  
d) Phase Transfer Method (Figure 2.4 D): Alkali halides have been used to catalyze 
glycosylation reaction. Silylated N2-acetyl guanine 15 reacts with 16 in the 
presence of KI and a crown ether in 1:1 MeCN:PhMe yielding 16 in 90% as a 7:3 
mixture of α:β anomers11. 
Even though the sodium salt method for glycosylation reaction has issues with regio- and 
stereo-selectivity, it has been accepted as the most effective methodology to perform 
glycosylation reactions for this substrate class, due to better results and ease of 
performing the procedure over other methods. However, it has been found that sodium 
salt is affected by the duration of the reaction, solvent, temperature and counter-ion. 
Investigation has proven that longer reaction time and polar solvents increase the relative 
ratio of α:β. The reason being that these factors individually or in some combination 
favor the anomerization of the sugar 512. More β-nucleoside would form initially, but 
could equilibrate over time to form more α product. Apart from these external factors, the 
inherent factors such as sterics and electronics of the heterocycle might influence the 
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results of the reaction as well. Considering both sterics and electronics of the nucleobase 
favor glycosylation at N9, the efficiency of coupling becomes a question of the rate of 
glycosylation vs. the rate of the anomerization of 5.  
 
2.2. Problems with Traditional Routes for our Modified Nucleoside Synthesis 
In terms of inherent factors, the sodium salt method works reasonably well for electron-
deficient nucleobase like chloropurine and even for aminopurines like adenine. But 
increasing electron density and steric bulk at the 3-position of 3-deaza-3-substituted 
purines affect the efficiency of glycosylation adversely. For minor groove modifications, 
we need to install a sterically demanding substituent in the 3-position of 3-deaza-3-
substituted purines. Some of these substituents increase the electron density of the 
heterocycle. When such substituents were used to couple with the sugar, 5, the 
regioselectivity was affected. For example, when 3-deaza-3-methyl-6-chloropurine 18 
was coupled to 5, only 39% of the desired β-N9 product 19 was obtained13, a reversal of 
regioselectivity (Scheme 2.5). Similar trends were observed with other 3-deaza-3-
substituted purines. This became a stumbling block for material throughput in our efforts 
to synthesize modified nucleosides required for minor groove modification. Large-scale 
glycosylations of 18 typically resulted in yields of 25-30% of 19, which was also quite 
difficult to separate from the N7 product 20. For our purposes we need to install the 
amine group at the 6-position. This was found to be unprecedentedly difficult. The 
amination of 19 required a harsh condition of overnight treatment with hydrazine 
followed by a 6 h reaction with Raney nickel that only resulted in a 50-60% yield. 
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Scheme 2.5: Reverse regioselectivity with 18. 
Further investigation showed that more of the desired N9 product consistently was 
obtained with increasing the size of the substituent at the 6-position. Our hypothesis is 
that a directing group, which can also have protecting group functionality, with sufficient 
steric bulk placed in the 6-position would increase the relative yield of the desired N9 
product. This should offer a significant improvement over the current methodology, for 
both modified purines like 3-deaza-3-substituted purines and unmodified purines. The 
use of such a group in the 6-position could also increase the solubility of the modified 
purine, thereby speeding up the reaction, which in turn could increase the yield of the 
glycosylation. Such an improvement would be a significant contribution to the field of 
nucleoside synthesis, since often it is necessary to settle for a glycosylation yield that is 
rather poor when considered in the overall context of organic synthesis, due to the lack of 
alternatives for difficult couplings. 
 
2.3. Development of Bulky Substituent at C6-position of Purines  
Various research groups have pursued the concept of a directing group. Bulky groups in 
the 6-position of purines are known to influence the N9:N7 ratios of alkylations14 and 
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glycosylations15. Robins16,  Mintas17, Demeunynck18 and others have worked in this area 
to develop different bulky functionality at the 6-position. Robins’ work involved 6-(1,2,4-
triazol-4-yl)purine 21 (Figure 2.2), 6-(2-substituted-imidazol-1-yl)purine 23 (R= H, Pr, 
Bu, Ph etc., for tuning the solubility of the purine) and 6-(imidizol-1-yl)purine. Mintas 
and Demeunynck investigated 6-pyrrole-substituted purines 22. Demeunynck also 
worked with 6-(1,2,4-triazol-4-yl)-2-6-diaminopurine. When 21 was alkylated, they 
yielded the N9 product exclusively19. However, the application of these groups for 
glycosylation reactions had serious problem as these purines are very polar and required 
solvent like DMF for the glycosylaton reaction. The results with 22 were not promising 
either. It was found that it is an inefficient directing group and removal of the group was 
a challenge.  The lipophilicity of 23 can be tuned to be suitable for glycosylation reaction. 
It afforded N9 products exclusively, but he α:β ratio was unfavorable. 
 
Figure 2.2: Selected examples of purines with different groups at 6-position of the 
purine. 
 
Some of these methodologies were investigated in our laboratory. Unfortunately they 
proved not suitable for glycosylation reactions involving 3-deaza-3-methyl-6-chloro 
purine 18. Some of results are discussed below. 
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a) 6-chloropurines was found to react with imidazoles at 65 °C in DMF in 
significant yield. However when 18 reacted with 2-isopropylimidazole, no 
product was detected (Scheme 2.6). The reactivity was found to be so poor that 
even after refluxing for 18 h, no appreciable amount of 25 was observed. 
 
Scheme 2.6. Failure to install 2-isopropylimidazole. 
b) In another attempt, a triazole was installed at the C6 position of 18. To do that, the 
6-Cl was first converted to an amino group by reacting 18 with anhydrous 
hydrazine at reflux for 24 h, then reduced with Raney nickel in H2O to obtain 60–
87% of 26. The yield of this reaction was variable, with 10–30% starting material 
typically recovered. Azine reagent did react with 26 to afford the 6-(1,2,4-triazol-
4-yl)-3-deaza-3-methylpurine 27. Reaction of this extremely insoluble compound 
with NaH in MeCN followed by 5 resulted in a N9-selective glycosylation, but 28 
was only isolated in 23% yield (Scheme 2.7). 
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Scheme 2.7: Attempt to use triazole as protecting/directing group. 
c) Further, deprotection of the imidazole blocking group was difficult20. For 6-(2-
substituted-imidazol-1-yl)-2-chloro-2′-deoxyadenosine nucleosides treatment with 
NH3/MeOH at 80 °C for 15 h in a pressure vessel gave 2-chloro-2′-
deoxyadenosine but separation of the imidazole from the nucleoside was 
problematic. For purines lacking the 2-chloro substituent, ammonolysis was more 
difficult. A selective deprotection of toluyl groups while keeping the 
protecting/directing group was necessary for our 3-deaza-3-substituted purines. 
2.4. Screening New Bulky Substituent at C6-position of Purines 
Since these groups failed to serve our purposes, the next choice was to try different cyclic 
anhydride. Initial efforts were made using phthaloyl group and cis-1,4-
cyclohexanedicarboxylic anhydride. Brief discussion about their success and limitations 
are described below.  
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a) Using phthaloyl group: The obvious choice of this group lies in the fact that it is 
commercially available. 26 was allowed to react with phthalic anhydride under 
refluxing conditions in anhydrous pyridine to yield a mixture of desired 29 and 
the incomplete diimide 30. Various separation methods including column 
chromatography and recrystallization could not separate 29 and 30. Instead 
refluxing the product mixture in excess SOCl2 for 2 h completely transformed the 
amide into 30 via the conversion of the acid of 29 into the acid chloride, which is 
highly reactive and cyclizes quickly to give 30 (Scheme 2.8).  
 
Scheme 2.8: Installing phthaloyl group on 26.  
When 30 reacted with 5, using the sodium salt method, for glycosylation reaction, 
only 15% of the desired β-N9 was observed. The overall yield of the reaction was 
65% but the remainder of the product was a mixture of other regio- and 
stereoisomers (α-N9, α-N7 and β-N7) (Scheme 2.9). Separation of these isomers 
was a challenge.   
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 Scheme 2.9: Glycosylation reaction of 30. 
Although it is reported that phthaloyl groups need hydrazine to be removed from 
aliphatic amines, most of the substrates we worked with were found to be labile 
under mild basic conditions. This makes it difficult to remove toluyl groups while 
keeping the phthaloyl group in place for phosphoramidite chemistry and 
subsequent incorporation in DNA. The amine can be re-protected but this adds 
more steps to get the phosphoramidite and, hence, is not an ideal solution. 
b) Using cis-1,4-cyclohexanedicarboxylic anhydride21: This was obtained by 
refluxing 32 in acetic anhydride for 5 h, followed by distillation (Scheme 2.10). 
There were two major road-blocks for using this group: i) it tends to form 
polyanhydrides fairly easily and, ii) the installation on simple adenine did not 
work. 
 
 Scheme 2.10: Synthesis of cis-1,4-cyclohexanedicarboxylic anhydride. 
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As a result this did not proved to be a good candidate for our purposes either. 
c) Using tetramethylsuccinic anhydride (M4SA)22: The use of M4SA as a 
protecting/directing group for purine glycosylation to achieve desired β-N9 
product resulted in a significant improvement compared to known methodologies. 
Slow addition of AIBN over 14 h to hot heptane resulted in homocoupling of the 
radical fragments to afford dinitrile 35. It was suspended in aqueous H2SO4 and 
heated for 2 h with vigorous stirring to obtain the anhydride in excellent yield 
(Scheme 2.11).   
 
Scheme 2.11: Synthesis of M4SA. 
36 was used to protect the C6-amino group of adenine and 26. This resulted in a 
mixture of desired dimide and mono-imide products. The mono-imide was 
converted to diimide by refluxing in excess thionyl chloride for 2 h. The total 
yield was in the range of 78-81% (Scheme 2.12). 
 
Scheme 2.12: Installing M4SA at C6 of adenine and 26. 
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The diimide was used for the glycosylation reaction via the sodium salt method. 
This proved to be a significant improvement over current methodology. These 
results will be discussed in detail and compared with other groups in section 2.6. 
The crystal structure of the M4SI of adenine was obtained and this provided 
valuable insights about why M4SI acts as an effective directing group for the 
glycosylation reaction. In the "face view" (Figure 2.3a) the four methyl groups 
can be observed positioned "umbrella-like" above the N7 edge of the adenine ring 
system. The distance between the imide carbonyl oxygen and the N7 nitrogen is 
3.1 Å, and that to C5 is 3.0 Å. These distances likely prevent a coplanar 
conformation between the imide and heterocycle, and in combination with the 
four methyl groups seem sufficient to limit access to the N7 by the incoming 
sugar.  The "edge view" (Figure 2.3b) illustrates that the plane of the imide 
functionality is in fact rotated 52° relative to the plane of the heterocycle, and this 
rotation is necessary to prevent the steric clash between the imide carbonyls and 
the N7 nitrogen and C5 carbon. 
 
 
Figure 2.3: Crystal structure of adenyl-N6-tetramethylsuccinimide. (a) face view, 
(b) edge view 
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With these findings, we decided to investigate further whether increasing the 
steric bulk at the sites of the methyl groups would optimize the directing ability of 
substituted succinimide derivatives.  It led us to explore the following two groups. 
d) Using 9,10-dihydroanthracene-9,10-dicarboxylic acid cyclic-anhydride: If steric 
bulk was the reason for the efficiency of M4SA then two aromatic rings would be 
an ideal candidate to test our hypothesis. To synthesize 9,10-dihydroanthracene-
9,10-dicarboxylic cyclic-anhydride (38), we started from commercially available 
cis-9,10-dihydroanthracene-9,10-dicarboxylic acid (37). A variety of conditions 
were tried, but we were unable to isolate the desired anhydride 38. In most of the 
cases we ended up getting either dimer or polymers (Scheme 2.13).  
 
Scheme 2.13: Attempts to synthesize 38. 
Another route to try was to directly install 37 at the C6-amino of adenine or 26. 
Unfortunately, we were never able to obtain the desired product. Since acid 
chlorides are more reactive than anhydrides, the corresponding acid chloride were 
prepared in situ and allowed to react with adenine. No product was isolated. After 
attempting different procedures to perform this reaction, it was decided to try the 
next anhydride. 
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e) Using bicyclo-1,1’-dicarboxylic acid cyclic-anhydride (Cy2SA) (39): This group 
was found be a highly efficient protecting/direction group. In the next 
section, we are going to discuss the synthesis and applicability of 
Cy2SA group as a protecting/directing group for purine glycosylation 
and compare its result with some of the other groups, especially M4SA 
group. 
 
 
2.5. Bicyclo-1,1’-dicarboxylic Acid Cyclic-anhydride as a Directing/Protecting 
Group 
The synthesis of Cy2SA is presented in Scheme 2.14. We could easily convert 1,1′-
azobis(cyclohexanecarbonitrile) (40) to the corresponding bicyclohexyl-1,1'-dinitrile (41) 
(Scheme 2.14) and then subject the product to strong acidic conditions23 to form the 
corresponding cyclic anhydride (39) (Scheme 2.14). The acidic cyclization step was 
tricky. During the first few attempts, only 12-15% product was isolated. The reaction was 
messy and it was difficult to monitor the reaction. A lot of side-products were obtained 
including incomplete hydrolyzed products, di-acid derivative etc. It was virtually 
impossible to separate them. After optimizing the conditions, it was found that the 
mixture of conc. sulfuric acid and water in the ratio of 2:1 was the optimum to carry out 
the reaction. The reaction mixture was heated at around 110 ᵒC (not higher than that) for 
1.5 hr followed by heating at 125 ᵒC for another 1.5 hr.   
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Scheme 2.14. Preparation of the Bicyclo-1,1’-dicarboxylic Acid Cyclic-anhydride 
(Cy2SA) group. 
 
Introduction of the Cy2SI protecting group to a selection of 6-amino purines is 
accomplished in a single step by simply refluxing the two reactants in the presence of 
DBU in pyridine (no thionyl chloride is necessary to effect the cyclization as in the case 
of M4SI installation
22).  The diimide product is obtained in reasonable yields. The crystal 
structure of the 3-methylated 3-deaz-4-methyladenine protected derivative illustrates 
(Figure 2.4) that the two cyclohexyl groups are crowding over the N7 of the purine base; 
specifically one methylene group from each of the cyclohexyl moieties are spatially 
positioned directly above the N7 (top view, Figure 2.4). 
 
 
 
Figure 2.4.  Crystal structure of the 3-deaza-3-methyl-adenine containing C6-amino 
protected with Cy2SA diimide from X-ray diffraction methods: a) side view and b) top 
view. 
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Glycosylation by the sodium salt method of unmodified or modified purine derivatives 
with C6-amino group is extremely effective with the Cy2SI protecting group in two 
aspects: (i) the –NH2 functionality, likely to react with the sodium hydride activation 
agent is absent and replaced by the much less reactive cyclicdiimide (Scheme 2.16), and 
(ii) the steric bulk of Cy2SI significantly blocks glycosylation at N7 resulting in higher 
yields of the desirable N9 product (Scheme 2.17, Figure 2.4). 
 
To investigate the efficiency of the Cy2SI group as directing group, we needed 
appropriate nucleobases. Adenine was used as the control base. We prepared two other 
bases (43 and 44) from 42 (Scheme 2.15 Top). One of the advantages of this new group, 
compared to M4SI, is that it imparts non-polarity to the molecule. As a result the 
conversion of 44 to 46 can be performed in one step due to the partial solubility of 44 in 
carbon tetrachloride (Scheme 2.15 Top). For the similar conversion with M4SI analogue 
(Scheme 2.16 Bottom), 47 needs to be first Boc-protected. That increases the non-
polarity of the molecule 48 which is then used to install the bromide to prepare 49. Then 
the Boc-group needs to be removed to get 50. Hence, when using Cy2SI in this specific 
conversion, the number of steps can be reduced and the overall yield can be increased. 
Once we have the bromide (44), this can be replaced by a variety of nucleophiles to 
introduce different minor groove modification functionality. For our purposes we decided 
to substitute the bromide of 44 by (4-methoxyphenyl)methanethiol (45) to prepare 46.  
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Scheme 2.15.Top- Preparation of modified nucleobases. Bottom- Three-step process of 
installing bromide functionality using M4SI. 
 
 
Scheme 2.17. Glycosylation of 3-substituted purines using bicyclo-1,1’-dicarboxylic acid 
cyclicdiimide protected amino group. 
 
 
The results of the glycosylation results have been tabulated in Table 2.1.  With the simple 
adenine heterocycle both M4SI and Cy2SI (51) result in regioisomeric ratios of greater 
than 99:1, but the β-N9-nucleoside tethering Cy2SI is isolated in 94% yield (54) (Table 
2.1) while the β-N9-nucleosdide tethering the M4SI is isolated in a respectable but 
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reduced yield of 71% with a slightly higher quantity of α-nucleosides.  Introduction of a 
methyl group at C3 as in 3-deaz-4-methyladenine (52) has a dramatic effect on both the 
product ratio and isolated yields. The N9:N7 ratio was found to be 6.4:1 for the M4SI –
protected derivative and substantially better at 20:1 for the Cy2SI-protected derivative 
(55).  The isolated yield remains better for the Cy2SI derivative (85% vs. 59%).  The 
results are promising when compared to chloro and phthalimide at the C6 position of the 
3-methyl-3-deazapurine (Table 2.1). Tethering even larger substituents does not 
substantially alter the results.  Using a (4-methoxyphenyl)methanethiol tethered to a 3-
methyl-3-deaza-adenine (53) would seem to offer a more significant steric challenge for 
these glycosylation conditions.  The N9:N7 ratio is 7:1 and 16:1 – very similar to the 
results of 3-deaza-4-methyladenine, and the isolated yields follow a similar trend at 57% 
and 82% (56), respectively (Table 2.1). It is also noteworthy that the substrates with 
Cy2SI also produce significantly lower amounts of the undesired α-isomers.  
 
Table 2.1. Isolated Glycosylation Yields. a See Ref. 23.  
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The reason of lower yields of the phthalimide and M4SI as protecting groups in the 
sodium salt methodology may be due to their instability in the basic reaction conditions. 
These groups fall off in these conditions and as a result the solubility of the 
corresponding bases decrease which lead to lower overall yields. Removals of these 
groups also lead to lower regioselectivity toward the desired β-N9 product. On the 
contrary, the Cy2SI is stable in the basic reaction conditions. Hence neither the solubility 
nor the regioselectivity is compromised. 
 
The hydrolytic stability of this protecting group is also advantageous towards their uses 
in the automated DNA synthesis. After glycosylation, the toluyl esters of 57 can be 
selectively removed by 7(M) ammonia in methanol at ambient temperature, while leaving 
the Cy2SI protecting group in place (58).  Alternatively, under conditions of conc. 
ammonia (aq.) at 55ᵒC, both the toluyl esters and the diimide protecting group are 
removed (Scheme 2.18). In the former case the partially protected nucleoside can be 
further converted to the DMTr-protected phosphoramidite (62) suitable for DNA 
synthetic procedures (Scheme 2.19) with the Cy2SI protecting group removed during 
standard DNA deprotection conditions. 
 
Scheme 2.18. Selective removal of toluyl groups and Cy2SI group.  
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Running the reaction in less polar solvents is thought to reduce the number of α-
nucleosides produced during the reaction24. Further investigation to develop 
directing/protecting groups is ongoing to facilitate the glycosylation reactions in non-
polar solvents like dichloromethane or dichloroethane.     
Scheme 2.19. Route to the preparation of Cy2SI-protected DMTr-nucleoside 
phosphoramidite.  
In summary, we have developed a new directing/protecting group that provides an 
effective route to access the 6-aminopurine-2’-deoxynucleosides with high 
regioselectivity towards the desired β-N9 product over β-N7; especially for the synthesis 
of valuable C3 substituted purines25. X-ray crystallography confirms that portions of both 
cyclohexyl groups are positioned to sterically block access of the N7 nitrogen so that 
glycosylation reactions occur with very high regiochemical control at N9. The favorable 
hydrolytic property of the Cy2SI group makes it an ideal protecting group for the 
phosphoramidite chemistry used in automated DNA synthetic procedures.  
 
 
 
77 
 
 
2.6. Experimental* 
 
General Procedures 
 
 
 
All reactions were carried out under an inert atmosphere with dry solvents under 
anhydrous conditions unless noted otherwise. Dry tetrahydrofuran (THF), diethyl 
ether (Et2O), N,N- dimethylformamide   (DMF),  pyridine  (pyr),  acetonitrile  
(MeCN),  and  dichloromethane (DCM) were obtained by passing commercially 
available pre-dried, oxygen-free formulations through activated alumina columns. 
Dry methanol (MeOH) was obtained by distillation from Mg(OMe)2. Yields refer to 
chromatographically and spectroscopically ( 1H NMR) homogeneous materials, unless 
otherwise  stated.  Reagents were purchased at the highest commercial quality and 
used without further purification, unless otherwise stated. Reactions were monitored 
by thin-layer chromatography (TLC) carried out on 0.25 mm Silicycle TLG- 
R10011B-323  60  Å  plates  using  UV  light  as  visualizing  agent  and  ceric  
ammonium molybdate (CAM) stain or 10% sulphuric acid solution (aq.) and heat as 
developing agents. Silicycle silica gel ( SiliaFlash P60, 60 Å, particle size 40-63 
µm) was used for flash column chromatography. Difficult separations were carried 
out using “chromatospec silica gel” (E. Merck Chromatospec silica gel (60 Å, 
particle size 15-40 µm). NMR spectra were recorded on Varian VNMRS 400, 
VNMRS 500, VNMRS 600, or INOVA 500 instruments and calibrated using 
residual undeuterated solvent (CDCl3: δH  = 7.26 ppm, δC  = 77.16 ppm, methanol-
                                                          
*
 The compound numbers are reset here for the rest of the chapter. 
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d4: δH = 3.31 ppm, δC = 49.00 ppm) as an internal reference. The following 
abbreviations are used to designate the multiplicities: s = singlet, d = doublet, t = 
triplet, q = quartet, quin = quintet, m = multiplet, br = broad. High-resolution mass 
spectra (HRMS) were recorded on a Waters LCT Classic or JEOL AccuTOF 
mass spectrometer using ESI (electrospray ionization) or DART (direct analysis in 
real time). 
I. Synthesis of Bicyclohexyl-1,1'-dicarboxylic anhydride 
 
Scheme 2.20. Synthesis of Bicyclohexyl-1,1'-dicarboxylic acid cyclic-anhydride 
(Cy2SA) 
 
[1,1'-bi(cyclohexane)]-1,1'-dicarbonitrile (2). To a flask of containing 1 (5 g, 20.463 
mmol) was added n-heptane (28 mL). The mixture was heated to 95oC for 36 h. The 
solution was allowed to cool to room temperature. The suspension was filtered and the 
residue was washed with hexanes (3×75 mL) to obtain light yellowish white product 
(4.129 g, 89%). 2: 1H NMR (500 MHz, CDCl3) δ 2.12 (d, J = 11.0 Hz, 4H), 1.90 - 1.73 
(m, 6H), 1.61 (d, J = 13.3 Hz, 8H), 1.25 -1.16 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
120.42, 46.45, 31.01, 24.87, 23.16; HRMS (ESI-TOF) calcd for [M + H]+ 234.19702, 
found: 234.19744. 
Bicyclohexyl-1,1'-dicarboxylic acid cyclic-anhydride (3). A solution of H2SO4 (44 
mL) in water (19 mL) was prepared and cooled to room temperature. To a flask 
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containing 2 (7.879 g, 36.425 mmol) was added the aq. H2SO4 solution. It was 
steadily heated at 115oC for 1h and 15min. Then the temperature was raised to 125oC 
and maintained for 1h and 15min. The solution was allowed to cool to room 
temperature. The resulting dark solution was extracted with diethyl ether (3×200 mL), 
the combined organic extracts were washed water (3×100 mL) followed by saturated 
NaHCO3 (3×100 mL), dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The resulting slightly yellowish residue was purified by flash colum 
chromatography (1:30 ethyl acetate: hexanes) to yield white amorphous powder (2.883 
g, 67%). 3: Rf= 0.42 (silica gel, 1:20 ethyl actate:hexane); 
1H NMR (400 MHz, CDCl3) 
δ 1.86 - 1.60 (m, 14H), 1.44 - 1.33 (m, 4H), 1.17 - 1.05 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 174.52, 52.95, 29.12, 25.39, 22.08; HRMS (DART-TOF) calcd for [M + H]
+ 
237.14907, found: 237.14909. 
 
II. Synthesis of 3-deaza-3-substituted Purine Substrates 
The 3-deaza-3-substituted substrates were prepared from the 3-deaza-3-methyl analog 
5. 
 Scheme 2.21. Synthesis 3-deaza-3-substituted substrates 
3-deaza-3-methyl-6-amino protected purine (6). To a flask containing 5 (1.2 g, 8.099 
mmol) and Cy2SA (5.742 g, 24.297 mmol) was added pyridine (80 mL) and DBU (3.63 
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mL, 24.297 mmol). The mixture was heated to reflux for 36 h. Volatiles were removed 
in vacuo and the residue co-evaporated with toluene (3 x 10 mL) to remove residual 
pyridine. The resulting brown oil was purified by flash column chromatography eluting 
with 1:25 MeOH:DCM to obtain of the compound 6 (2.552 g, 86%) as a white 
amorphous powder. 6: Rf  = 0.32 (silica gel, 1:20 MeOH:DCM); 
1H NMR (500 MHz, 
CDCl3) δ 8.00 (s, 1H), 7.36 (s, 1H), 2.21 (s, 3H), 1.98 (dd, J = 25.2, 11.7 Hz, 8H), 1.79 - 
1.69 (m, 6H), 1.60 - 1.53 (m, 4H), 1.25 - 1.17 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
181.46, 142.94, 140.96, 139.58, 135.77, 135.69, 119.22, 52.07, 30.21, 25.65, 22.47, 
14.01; HRMS (DART-TOF) calcd for [M + H]+ 367.21340, found: 367.21464.. 
 3-deaza-3-bromomethyl-6-amino protected purine (7). To a flask containing 6 (1.5 g, 
4.093 mmol) was added N-bromosuccinimide (1.092 g, 6.140 mmol, recrystallized 
from hot H2O), benzoyl peroxide (99 mg, 0.409 mmol), and 120 mL of CCl4 
(reagent grade, not  anhydrous).  The mixture was heated to reflux with stirring.  
After 5 hr additional NBS (364 mg, 2.047 mmol) and (BzO)2  (99 mg, 0.409 mmol) 
were added. After 8 hr (total), all the starting material was consumed. The reaction was 
allowed to cool to rt and filtered to removed succinimide. Volatiles were removed in 
vacuo and the residue purified by flash column chromatography eluting with 3 : 2  
e t h y l  a c e t a t e :  h e x a n e  to afford the desired product as a white foam (0 .966  
g ,  53% ) . 7:  Rf  = 0.23 (silica gel, 1 :1  e thyl  acet a te :  hexane ); 1H NMR (500 
MHz, CD3OD) δ 8.44 (s, 1H), 8.41 (s, 1H), 4.98 (s, 2H), 2.09 – 1.93 (m, 8H), 1.75 – 
1.70 (m, 6H), 1.63 (dd, J = 13.0, 9.2 Hz, 4H), 1.32 - 127 (m, 3.5 Hz, 2H); 13C NMR (126 
MHz, CD3OD) δ 181.59, 146.46, 141.70, 139.16, 122.82, 106.42, 53.17, 31.01, 26.67, 
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26.08, 23.55; HRMS (DART-TOF) calcd for [M+ H]+  445.12391, found: 445.12421. 
3-deaza-3-(4-methoxyphenyl)methanethiolmethyl-6-amino protected purine (9). 
To a flask containing sodium hydride (53 mg, 2.19 mmol) was added DMF (15 mL) 
followed by the thiol reagent 8 (0.31 mL, 2.19 mmol). The mixture was stirred at 25oC 
for 30 min. The compound 7 (0.65 g, 1.460 mmol) was added and allowed to stir for 
another 10 h at room temperature. The TLC indicated the reaction was complete. 
Volatiles were removed in vacuo and the residue purified by flash column 
chromatography eluting with 1:40 MeOH:DCM to afford the  desired product as a 
white foam (0.583 g, 77%). 9: Rf=  0.35 (silica gel, 1:25 MeOH:DCM ); 1H NMR (500 
MHz, CD3OD) δ 8.33 (s, 1H), 8.14 (s, 1H), 7.16 (d, J = 8.5 Hz, 2H), 6.87 – 6.80 (m, 
2H), 4.01 (s, 2H), 3.78 (s, 3H), 3.64 (d, J = 8.3 Hz, 2H), 2.11 – 1.94 (m, 8H), 1.79 – 
1.70 (m, 6H), 1.63 (td, J = 13.0, 3.9 Hz, 4H), 1.33 – 1.28 (m, 2H); 13C NMR (126 MHz, 
CD3OD) δ 180.39, 158.81, 144.46, 139.86, 131.28, 129.66, 129.40, 113.94, 113.47, 
54.25, 51.64, 34.69, 29.61, 29.14, 25.27, 22.14; HRMS (DART-TOF) calcd for [M+ 
H]+  519.2430, found: 519.2446. 
6-Amino protected adenine (10). To a flask containing adenie (0.25 g, 1.85 mmol) and 
Cy2SA (1.312 g, 5.55 mmol) was added pyridine (20 mL) and DBU (0.83 mL, 5.55 
mmol). The mixture was heated to reflux for 20 h. Volatiles were removed in vacuo and 
the residue co-evaporated with toluene (3×10 mL) to remove residual pyridine. The 
resulting brown oil was purified by flash column chromatography eluting with 1:30 
MeOH:DCM to obtain of the compound 10 as a white amorphous powder (0.582 g, 89% 
). 10: Rf  = 0.42 (silica gel, 1:20 MeOH:DCM); 1H NMR (500 MHz, CD3OD) δ 8.93 
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(s, 1H), 8.53 (s, 1H), 2.00 - 1.90 (m, 8H), 1.77 - 1.67 (m, 6H), 1.59 (td, J = 13.5, 4.1 Hz, 
4H), 1.30 - 1.20 (m, 2H); 13C NMR (126 MHz, CD3OD) δ 180.63, 153.22, 147.68, 
144.61, 53.50, 30.87, 26.62, 23.50; HRMS (DART-TOF) calcd for [M+ H]+  
354.19300, found: 354.19345. 
III. Synthesis of the nucleosides of 6, 9 and 10 
The nucleosides of the protected nucleobases 6, 9 and 10 were prepared as shown 
below. 
 
Scheme 2.22. Glycosylation reactions of the protected nucleobaese 
General Procedure: To a flask containing protected nucleobase and NaH (1.5 eqvt.), 
DMF (0.05 (M) solution) was added and stirred for 30 min at room temperature. The 
sugar (11)  
(1.8 eqvt.) was added to the mixture and stirred for another 2 hr at room temperature.  
The resulting cloudy solution was filtered through celite and rinsed with acetone. The 
filtrated was concentrated in vacuo and purified by column chromatography to yield the 
white foam. 
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. Nucleoside β9:β7 %yield β9 Total %yield of 
other isomers 
12 20:1 85 12 
13 16:1 82 10 
14 >99:1 94 3 
 
Characterization of 12: Rf= 2.20 (silica gel, 1:3 ethyl acetate:hexanes). Purified by 
gradient column chromatography ranging from 1:4 to 2:3 ethyl acetate:hexanes; 1H 
NMR (500 MHz, cdcl3) δ 8.24 (s, 1H), 8.22 (s, 1H), 7.95 – 7.92 (m, 2H), 7.87 – 7.84 
(m, 2H), 7.30 – 7.27 (m, 2H), 7.24 – 7.21 (m, 2H), 6.63 (t, J = 6.8 Hz, 1H), 5.71 – 5.67 
(m, 1H), 4.68 – 4.57 (m, 3H), 2.80 (qd, J = 7.9, 4.3 Hz, 2H), 2.70 (d, J = 0.7 Hz, 3H), 
2.43 (d, J = 5.2 Hz, 3H), 2.40 (s, 3H), 2.08 – 1.94 (m, 8H), 1.77 – 1.66 (m, 6H), 1.52 
(qd, J = 13.1, 3.9 Hz, 4H), 1.18 (tdd, J = 12.5, 8.1, 4.4 Hz, 2H).); 13C NMR (126 MHz, 
CDCl3) δ 180.31, 166.26, 165.93, 144.80, 144.33, 143.50, 141.74, 139.46, 137.95, 
137.21, 129.88, 129.76, 129.48, 126.65, 126.36, 117.80, 85.41, 82.82, 74.62, 63.96, 
52.13, 39.54, 30.41, 29.99, 25.90, 22.61, 21.87, 21.78, 15.83; HRMS (ESI-TOF) calcd 
for [M+ H]+  741.3264, found: 741.3242. 
Characterization of 13: Rf= 2.26 (silica gel, 1:3 ethyl acetate:hexanes). Purified by 
gradient column chromatography ranging from 1:5 to 3.2:10 ethyl acetate:hexanes; 1H 
NMR (500 MHz, CDCl3) δ 8.20 (d, J = 6.2 Hz, 1H), 8.16 (s, 1H), 7.99 - 7.95 (m, 2H), 
7.86 - 7.83 (m, 2H), 7.28 - 7.24 (m, 2H), 7.24 - 7.20 (m, 4H), 6.85 - 6.82 (m, 2H), 6.74 
(t, J = 6.6 Hz, 1H), 5.69 - 5.65 (m, 1H), 4.61 - 4.53 (m, 2H), 4.50 (dd, J = 7.2, 3.9 Hz, 
1H), 4.18 - 4.14 (m, 1H), 3.78 (s, 3H), 3.64 (d, J = 1.8 Hz, 2H), 2.82 - 2.76 (m, 2H), 
2.44 (s, 3H), 2.40 (s, 3H), 2.03 (dd, J = 18.2, 8.0 Hz, 8H), 1.73 (dd, J = 32.1, 12.4 Hz, 
6H), 1.56 – 1.48 (m, 4H), 1.22 - 1.17 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 180.25, 
84 
 
166.26, 165.97, 159.00, 144.75, 144.30, 143.52, 142.02, 139.32, 139.16, 137.92, 
130.27, 130.01, 129.78, 129.48, 129.27, 126.73, 126.43, 118.77, 114.22, 85.68, 82.52, 
74.29, 63.91, 55.42, 52.24, 38.68, 35.43, 30.50, 30.02, 29.94, 25.91, 22.64, 21.89, 
21.82; HRMS (ESI-TOF) calcd for [M+ Na]+  893.3560, found: 893.3564. 
Characterization of 14: Rf= 2.24 (silica gel, 1:3 ethyl acetate:hexanes). Purified by 
gradient column chromatography ranging from 1:4 to 3.5:10 ethyl acetate:hexanes; 1H 
NMR (500 MHz, cdcl3) δ 8.93 (s, 1H), 8.29 (s, 1H), 8.00 – 7.95 (m, 2H), 7.92 – 7.88 
(m, 2H), 7.28 (d, J = 8.0 Hz, 2H), 7.24 (t, J = 7.5 Hz, 2H), 6.60 (dd, J = 8.4, 5.7 Hz, 1H), 
5.81 (d, J = 6.2 Hz, 1H), 4.73 (td, J = 5.9, 2.9 Hz, 1H), 4.66 (dt, J = 7.4, 4.4 Hz, 2H), 
3.15 (ddd, J = 14.5, 8.5, 6.3 Hz, 1H), 2.85 (ddd, J = 14.2, 5.7, 1.9 Hz, 1H), 2.44 (s, 3H), 
2.40 (s, 3H), 2.04 – 1.95 (m, 8H), 1.81 – 1.69 (m, 6H), 1.59 – 1.49 (m, 4H), 1.19 (dtd, J 
= 12.7, 9.0, 3.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 179.10, 166.28, 166.00, 
153.32, 152.67, 145.45, 144.66, 144.25, 144.02, 130.34, 129.94, 129.79, 129.41, 
126.79, 126.49, 85.20, 83.30, 75.13, 64.10, 53.94, 52.63, 37.96, 30.07, 29.94, 29.40, 
25.78, 22.51, 21.86, 21.78; HRMS (ESI-TOF) calcd for [M+ Na]+  728.3060, found: 
728.3028. 
Determination of regioselectivity of 12 and 13: Regioselectivity was determined by 
NOESY experiment. The important interactions (Figure 1) has been indicated. There 
were no interactions of any of the hydrogens of the Cy2SI with the C1’ hydrogen. This 
proves that the 12 and 13 were the N9 products, and not N7.   
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Figure 1: NOESY signals from NOESY experiment for compound 12 and 13. 
IIIa. Details of M4SI (tetramethylsuccinimide) derivatives of 7, 9 and 13 
9a was synthesized from 7a following the similar procedure used to convert 7 to 9. The 
reaction time and yield were 13 h and 74% respectively. General procedure for 
glycosylation was performed to couple 9a with 11 to yield 57% of the desired β-N9 
product.  
 
IV. Selective removal of toluyl groups 
 
Scheme 2.23. Removal of toluyl groups without cleaving the Cy2SI group 
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 General Procedure: To a flask containing the nucleoside was added 7(M) NH3 
containing methanol (0.05(M) solution). It was stirred at room temperature for 20 hr. 
Solvent was removed in vacuo and resulting crude was purified by flash column 
chromatography to yield white solid. 
Yield of 15 and 16 was found to be 89% and 92% respectively. 
Characterization of 15: 1H NMR (500 MHz, CD3OD) δ 8.68 (s, 1H), 8.16 (s, 1H), 6.71 
(t, J = 6.3 Hz, 1H), 4.58 (dt, J = 6.1, 4.3 Hz, 1H), 4.06 (q, J = 3.6 Hz, 1H), 3.73 (ddd, J = 
33.6, 12.1, 3.7 Hz, 2H), 2.83 – 2.75 (m, 1H), 2.798 (s, 3H), 2.58 (ddd, J = 13.4, 6.0, 4.5 
Hz, 1H), 2.16 – 1.92 (m, 8H), 1.72 (dd, J = 20.7, 9.2 Hz, 6H), 1.61 (t, J = 12.2 Hz, 4H), 
1.33 – 1.24 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 180.46, 143.89, 141.74, 139.81, 
136.61, 119.61, 87.93, 85.46, 70.59, 61.18, 51.65, 40.44, 29.54, 25.25, 22.13, 14.26; 
HRMS (DART-TOF) calcd for [M+ H]+  483.26074, found: 483.25878. 
Characterization of 16: 1H NMR (500 MHz, CD3OD) δ 8.93(s, 1H), 8.75 (s, 1H), 6.59 
(t, J = 6.6 Hz, 1H), 4.64 - 4.60 (m, 1H), 4.06 (q, J = 3.6 Hz, 1H), 3.83 (dd, J = 12.1, 3.5 
Hz, 1H), 3.76 (dd, J = 12.1, 4.1 Hz, 1H), 2.91 - 2.85 (m, 1H), 2.52 (ddd, J = 13.6, 6.4, 
3.8 Hz, 1H), 2.01 - 1.91 (m, 8H), 1.72 (dd, J = 21.1, 9.7 Hz, 6H), 1.58 (dd, J = 20.3, 7.6 
Hz, 4H), 1.30 - 1.22 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 179.19, 153.20, 151.69, 
144.58, 130.36, 88.20, 85.21, 71.05, 61.69, 52.25, 39.90, 29.37, 25.20, 22.07; HRMS 
(DART-TOF) calcd for [M+ H]+  470.24034, found: 470.23837. 
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V. Synthesis of phosphoramidite from 15 
 Scheme 2.24. Synthesis of DMTr-protected phosphoramidite of 15 
Compound 17: To a flask containing 15 (35 mg, 0.073 mmol) dissolved in pyridine 
(0.8 mL) was added TEA (14 μL, 0.102 mmol), DMTrCl (30 mg, 0.087 mmol), and 
DMAP (0.9 mg, 0.007 mmol). The reaction was allowed to stir at rt for 5 h. TLC 
analysis indicated that some starting material remained, and so additional DMTrCl (5 
mg, 0.015 mmol) was added. TLC after another 8 h indicated complete consumption of 
starting material. Volatiles were removed in vacuo and the solid residue was then 
purified by flash chromatography (silica gel was washed with 1% TEA in 1:50 
MeOH:DCM) eluting with 1% TEA in 1:50 MeOH:DCM to afford 22 as a white foam 
(48 mg, 84%). 17: Rf= 0.23 (silica gel, 1:50 MeOH:DCM); 
1H NMR (500 MHz, 
CDCl3) δ 8.16 (s, 1H), 8.11 (s, 1H), 7.41 - 7.35 (m, 2H), 7.30 - 7.18 (m, 7H), 6.81 (dd, J 
= 8.9, 1.6 Hz, 4H), 6.47 (t, J = 6.3 Hz, 1H), 4.51 (dd, J = 9.5, 4.3 Hz, 1H), 4.08 (dd, J = 
8.7, 4.4 Hz, 1H), 3.78 (s, 6H), 3.38 (dd, J = 10.2, 4.4 Hz, 1H), 3.28 (dd, J = 10.2, 5.1 
Hz, 1H), 2.63 (s, 3H), 2.49 (tdd, J = 13.1, 11.7, 6.0 Hz, 2H), 2.13 - 1.93 (m, 8H), 1.77 - 
1.63 (m, 6H), 1.56 - 1.46 (m, 4H), 1.38 (dd, J = 13.9, 6.8 Hz, 2H); 13C NMR (126 MHz, 
CDCl3) δ 180.31, 158.65, 144.42, 143.05, 142.00, 139.33, 137.61, 137.18, 135.52, 
135.42, 130.03, 129.98, 128.03, 127.98, 127.01, 117.98, 113.29, 86.75, 85.74, 84.90, 
72.18, 63.67, 55.24, 51.99, 41.35, 30.27, 29.93, 25.78, 22.50, 15.73; HRMS (ESI-TOF) 
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calcd for [M+ H]+  785.3914, found: 785.3941. 
Compound 19: To a flask containing 17 (35 mg, 0.045 mmol) dissolved in MeCN (0.9 
mL) was added tetrazole (3 mg, 0.045 mmol) followed by 2-cyanoethyl N,N,N’,N’-
tetraisopropylphosphane(18) (30 μL, 0.089 mmol) dropwise. The mixture was allowed 
to stir at rt for 12 h, after which TLC indicated that the reaction was complete. Water 
(0.1 mL) was added and stirring continued for 10 min. The reaction mixture was diluted 
with DCM (5 mL) and washed with aq. saturated NaHCO3 solution (2×2 mL) and brine 
(1×2 mL). The organic layer was separated and dried with Na2SO4, then filtered and 
dried in vacuo. It was dissolved in 0.2 and mL of DCM. To this 2 mL of hexane was 
added when the product crushed out as white solid. The liquid phase was removed. This 
process of dissolving and precipitation was carried out 5 times. Then the white residue 
was purified by short flash column chromatography (silica gel washed with 1% TEA in  
0.5:9.5 MeOH:DCM) eluting with 0.5:100 MeOH:DCM to afford 19 as a white foam 
(28 mg, 63%, 1:1 mixture of diasteriomers). 19: Rf= 0.29 (silica gel, 1:50 
MeOH:DCM); 31P NMR (202 MHz, CDCl3) δ 149.48, 149.07. 
HRMS (ESI-TOF) calcd for [M+ H]+  985.4993, found: 985.4982. 
VI. Removal of the directing/ protecting group 
 
Compound 20: The nucleoside 16 (20 mg, 0.043 mol) was taken in a vial. To this 
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conc. NH3 (aq.) (2 mL) was added. It was allowed to remain in the water bath at 55oC 
for 12 h. The water was removed in vacuo and the obtained crude was purified by 
HPLC to obtain compound 20. 20: 1H NMR (500 MHz, CD3OD) δ 8.34 (s, 1H), 8.20 
(s, 1H), 6.45 (dd, J = 7.9, 6.1 Hz, 1H), 4.60 (dt, J = 5.7, 2.6 Hz, 1H), 4.09 (dd, J = 5.7, 
2.9 Hz, 1H), 3.82 (ddd, J = 50.8, 12.3, 3.1 Hz, 2H), 2.83 (ddd, J = 13.6, 7.9, 5.8 Hz, 
1H), 2.43 (ddd, J = 13.4, 6.0, 2.7 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ 157.52, 
153.49, 149.95, 141.54, 120.86, 89.91, 87.15, 73.06, 63.65, 41.57; HRMS (DART-
TOF) calcd for [M+ H]+  252.10966, found: 252.11006. 
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1H NMR of Compound 2 
 
13C NMR of Compound 2 
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1H NMR of Compound 3 
 
13C NMR of Compound 3 
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1H NMR of Compound 6 
 
13C NMR of Compound 6 
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1H NMR of Compound 7 
 
13C NMR of Compound 7 
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1H NMR of Compound 9 
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1H NMR of Compound 10 
 
13C NMR of Compound 10 
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1H NMR of Compound 12 
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1H NMR of Compound 13 
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1H NMR of Compound 14 
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1H NMR of Compound 15 
 
13C NMR of Compound 15 
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1H NMR of Compound 16 
 
13C NMR of Compound 16 
 
101 
 
1H NMR of Compound 17 
 
13C NMR of Compound 17 
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31P NMR of Compound 19 
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1H NMR of Compound 20 
 
13C NMR of Compound 20 
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Chapter 3 
Cyclic Oligonucleotides 
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Background 
As we have discussed in section 1.6,  the preorganization of modified oligonucleotides is 
an important aspect for sequence specific recognition of a single-stranded nucleic acid. 
One of the strategies to rigidify the nucleotide units is by locking the sugar moiety in a 
fixed conformation by introducing new covalent bonds. Some of the successful 
candidates are discussed below.  
 
3.1. Rigidified Nucleic Acids  
 
3.1.1. Bicyclo-DNA 
In this approach the preorganization of DNA is achieved by rigidifying the normally 
flexible furanose ring by chemical modification. This oligonucleotide analogue has been 
termed “bicyclo-DNA”1. The modification is done by the addition of an ethylene bridge 
from C-3′ to C-5′, adding a second five-membered ring to the natural structure (2) (Figure 
3.1).  
 
Figure 3.1: Illustration of the structure of Bicyclo-DNA compared to DNA.  
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This analogue has been found in some cases to hybridize strongly with an RNA strand; 
for example, a strand of bicyclo-DNA with adenine bases binds poly(U) more tightly than 
does a similar strand of natural adenine-containing DNA, and similar effects have been 
observed in triplex formation. Some sequences of bicyclo-DNA bind a single-stranded or 
duplex complement with lower affinity than natural DNA; in part this may be due to the 
adoption of an unfavorable ring conformation1.  
 
3.1.2. Hexose-DNAs and RNAs 
Six-membered rings are known to be more rigidified than five-membered rings2. 
Furanose sugars have a low barrier to inter-conversion of ring conformers, while 
pyranoses are generally much more stabilized in a chair conformation. Several analogues 
of DNA and RNA of this class have been designed and synthesized in which the furanose 
ring is expanded to a six-membered ring (Figure 3.2)2.  
 
Figure 3.2: Examples of Hexose-DNA and RNA. 
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One fascinating example of this concept is the pyranosyl-RNA analogue (pRNA) (6) of 
Eschenmoser. This structure contains the same number of carbons as RNA but with six- 
membered rings rather than five-membered ones, and with one fewer freely rotating 
internucleotide bond (Figure 3.2). Hybridization studies have shown that oligonucleotides 
constructed with this backbone bind to RNA complementary strands very strongly; this 
result is attributed in large part to the conformational rigidity of the modified sugar–
phosphate backbone2. 
 
3.1.3. Locked Nucleic Acids (LNA)   
Locked nucleic acids (LNA) were introduced in 1998 by Wengel and co-workers in order 
to generate monomers which will favorably lock the sugar in the C3’-endo 
conformation3. In this modification, the C2’-oxygen of ribonucleosides is tethered to the 
C4’ via a methylene group. The modification rigidifies the sugar pucker permanently to 
C3’-endo conformation as shown in Figure 3.3b. Subsequently various analogues of these 
original LNAs have been synthesized (Figure 3.4)4. 
 
  
Figure 3.3. Conformation of sugar pucker. a) In DNA and RNA; b) In LNA. 
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LNA is a unique class of rigidified oligonucleotide because of their remarkable desirable 
binding affinity5, stability in presence of nucleases6 and serum7 and low toxicity8.  
 
Figure 3.4. Selected Examples of LNAs. 
 
3.1.4. Cyclic Oligonucleotides 
Cyclic oligonucleotides are another class of rigidified oligonucleotides. The main feature 
of this class is that the nucleobase is locked in the anti-conformation with respect to the 
sugar by tethering the C5’ of the sugar with the C8 of the purine or C6 of the pyrimidine. 
Broadly, cyclic nucleosides can be categorized in two sub-categories. First, where the 
sugar and the base are directly connected involving the mentioned atoms9. Second, where 
they are connected via extended chains. We will designate the first and second sub-
category as Generation 1 and Generation 2 respectively. 
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Some of the Generation 1 analogues like 8,5’-cyclopurine represent a unique class of 
naturally occurring, helix-distorting DNA lesions that result in a covalent linkage 
between the sugar and base moieties of a single nucleoside, most commonly at 2’-
deoxypurines10.  
 
Figure 3.5. Example of Generation 1: Two epimers of 8,5-cyclo-2’-deoxyadenosine. 
 
Our group has studied extensively the binding, selectivity and affinity of the Generation 1 
containing oligonucleotides. Analogues of diastereomerically pure dA (Figure 3.5), dU, 
U and dG have been synthesized and incorporated in the DNA. The modified strands 
were used to bind native DNA, RNA and modified DNA strands. We will discuss the dG 
analogue in section 3.2. In all the cases, the Tm and the change in hyperchromicity were 
lower than the native DNA duplex control. Our investigation has proven that the linkage 
between C5’ and C8 “pulls” the base back from its native Watson and Crick bonding 
position and create an unfavorable  angle, leading to non-effective hydrogen bonding 
with its corresponding base partner on the complimentary strand (Figure 3.6). 
   
 
Figure 3.6: Overlay of dU and FdU 
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With these results, we decided to develop the Generation 2 cyclic-nucleotides. My 
colleague, Yueh Han, and I collaborated to synthesize 6,8’-cyclo-2’-deoxyadenosine. Our 
goal with 6,8’-cyclo-2’-deoxyadenosine is to connect C5’ and C8 via a methylene group. 
It should be able to address two issues- i) we could effectively “push” back the base 
closer to the original position; and ii) impart some degree of flexibility in the linkage so 
that the base can an adopt favorable  angle. Both of these should lead to better 
preorganization of these nucleosides. Details of the synthesis will be discussed in section 
3.3. 
 
3.2. Synthesis of 8,5-(S)-cyclo-2’-deoxyguanosine* 
The synthesis starts with readily available 2’-deoxyguanosine (Scheme 1). The 2-amino 
group is first protected with standard isobutyric group (2). This is followed by the 
selective installation of tosyl-group at 5’-hydroxyl group (3). This step is fairly selective 
for 5’-hydroxyl over 3-hydroxyl because the former is primary alcohol and preferentially 
react first. A trace amount of di-protected product was observed. In the next step the free 
3’-hydroxyl was protected with TIPS-group (4). This reaction was found to be extremely 
slow. Attempts were made to heat the reaction mixture. However it was found that 
heating makes the reaction messy. It was also observed that without AgNO3 the reaction 
was even slower. 
                                                        
* The compound numbers are reset here for the rest of Chapter 3. All the figures, schemes 
and references are continued. 
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Scheme 3.1: Route to synthesize 8,5-(S)-cyclo-2’-deoxyguanosine 
In the next step, an iodo-group (5) was installed at C5’ by an SN2 reaction. This is a very 
high yielding step with no other side products. The next step is the cyclization reaction by 
heating the iodo-compound (5) with zinc in pyridine to give compound 6. To reinstall the 
aromiticity, compound 6 was oxidized by a reducing agent, tetachloroquinone, to give 
compound 7. The overall yield of these two steps was 46%. It was not great; but it was 
reproducible. In another attempt, a combination of AIBN and Bu3SnH was used. This 
radical based methodology was found to be inefficient. A variety of conditions were 
tried. The maximum yield of desired product that was observed was only 19%. This 
major product of this reaction was compound 7a.  
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Scheme 3.2: Failed attempt to cyclize 5 with AIBN and Bu3SnH. 
 
We needed the hydroxyl group back at the C5’position. To do that, first a keto-group was 
introduced (8) at that position by selenium dioxide in reasonable yields. Reduction of 
keto-compound with NaBH4 produced (S)-epimer exclusively. Nucleophilic attack by a 
charged nucleophile, in this case a hydride anion, on the unsaturated trigonal center of the 
carbonyl of a ketone occurs following the Bürgi–Dunitz angle of around 107°. The 
reason of the high selectivity is the steric hindrance of the sugar moiety that discourages 
the attack of the hydride from the top face of the six-membered ring according to the 
Bürgi–Dunitz angle. However, the alternative attack of the hydride from the bottom face 
is unhindered. This leads to the (S)-epimer (9) exclusively.   
Scheme 3.3: Synthesis of the phosphoramidite 11. 
To incorporate compound 9 in the modified DNA sequence, we need to prepare its 
corresponding phosphoramidite (11). In general the requirement is to install a DMTr-
group at C5’- hydroxyl and phosphoramidite at the C3’-hydroxyl. Numerous attempts 
were made to install the DMTr-group at C5’-hydroxyl. It resulted in an insignificant 
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amount of the desired product. Either the starting material was recovered or, in some 
instances  heating the reaction mixture led to the decomposition of the starting material. It 
was realized that after the cyclization, the rigidity of the molecule increases the bulk in 
the vicinity of the reaction center, C5’-position. DMTr-group itself is a bulky group. So 
the spatial steric hindrance might be the reason of the failure of the step.  
 
Alternatively, we needed a group that does not have a huge steric requirement but should 
be cleaved during the DMTr-deprotection step of the automated DNA synthesis. It was 
found that ethyl vinyl ether (EVE) is a suitable candidate. When EVE was allowed to 
react with compound 9, it gave two diastereomers (10) in an excellent overall yield. The 
two diastereomers co-migrated on TLC and silica gel column chromatography. It was 
virtually impossible to separate them. The single molecular peak in high resolution mass 
spectrometry confirmed that the product was clean. The proton NMR confirmed the 
presence of the two diastereomers. Since these diastereomers would not affect the DNA 
synthesis, the mixture of products was used for the next step. In the next step, the TIPS 
group was removed using TBAF, followed by installation of phosphoramidite group at 
the C3’-hydroxyl (11). The presence of the two phosphorus diastereomers and the two 
EVE diastereomers could be confirmed by the presence of four phosphorus resonances in 
the final product. It is now ready to be incorporated in DNA sequence. 
 
With this phosphoamidite in hand we prepared three 12 nucleotides long self-
complementary sequences (Entry 2-4, Table 3.1). The corresponding native DNA strand 
(Entry 1) was also prepared. Before we study the binding properties of thse modified 
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strands, we need to make sure that they get incorporated in the DNA strands. This was 
challenging because we have replaced the widely used DMTr-group by EVE-group at the 
C5’ position for the cyclo-dG derivative. The DNAs were characterized by MALDI-mass 
spectrometry. The results are tabulated in Table 3.1. 
 
Table 3.1. Sequences and Molecular Masses (G* = Modified dG) 
Entry Sequence (5’→3’) Calculated 
Mass 
Found 
Mass 
Comments 
1 d(GCTCACGTGAGC) 3645.7 3646.1 Confirmed. 
2 d(G*CTCACGTGAGC) 3643.6 3643.9 Confirmed, although some 
without cyclo-dG is seen 
(3316.5). 
3 d(GCTCACGTG*AGC) 3643.6 3644.42 Confirmed, but with a large 
amount of minus cyclo-dG 
(3316.7). 
4 d(GCTCACG*TGAGC) 3643.6 3644.5 Confirmed, but with a large 
amount of minus cyclo dG 
(3316.7). 
 
The native sequence was pure (Entry 1). But the results of the DNAs containing the 
modification were a little puzzling. All of them showed we had the required strand. 
However, the samples also contained a strand containing 11 nucleotides. The modified 
nucleotide was missing. Entry 2 can be rationalized from the fact that the HPLC trace of 
product had a mild shoulder that could not be completely resolved. That explains why we 
had some strands without the modification. For entry 3 and 4, the modified nucleotide is 
within the sequence and the HPLC traces looked clean. But still DNA strands without the 
modification were observed. The only reason it might happen is if the coupling efficiency 
of the modification was reasonably poor. As a result, there were growing DNA strands 
without the modification that were not completely capped during the capping step of the 
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automated DNA synthesis. Hence they kept on growing, resulting in DNA strands with 
11 residues. The HPLC purification might not be efficient enough to resolve the 
difference of one nucleotide. The only way to confirm this would be to perform gel 
purification. This is currently being pursued. With the pure strands it would be possible to 
perform further studies.          
 
3.3. Synthesis of 6,8’-cyclo-2’-deoxyadenosine 
The previous report closest to our molecules was made by Ueda et al11. They synthesized 
the ribose analogue, 6,8’-cycloadenosine. Not too many biophysical or biochemical 
studies were performed with the oligonucleotides containing 6,8’-cycloadenosine. 
Neither was the issue of stereochemistry at the newly generated C5’ chiral explored. One 
of the reasons might have been the difficulty to synthesize this molecule in reasonable 
quantity to investigate their properties. Inspired from this and the limitations from the 
Generation 1 cyclo-nucleosides, we decided to develop a route to synthesize 6,8’-cyclo-
2’-deoxyadenosine to investigate their biophysical properties. 
 
The synthesis starts with 2’-deoxyadenosine (Scheme 4).  The multi-step one-pot 
procedure to protect the C6-amino group (12) is followed by protection of 5’-OH and 3’-
OH by DMTr and TIPS groups (13 and 14) respectively. It was followed by the 
regeneration of 3’-hydroxyl by the removal of DMTr-group (15). The next step was to 
oxidize the 5’-OH to aldehyde (16). A variety of conditions were tried including Swern 
oxidation12, Ley oxidation (using TPAP and NMO)13, PCC oxidation14 and Dess-Martin 
oxidation15. It was observed that the Dess-Martin oxidation gave the best results. It was a 
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clean, quick and efficient method for controlled oxidation of the primary hydroxyl to 
aldehyde. To introduce the extra carbon at C5’, the aldehyde was allowed to react with 
trimethylsilyl diazomethane to generate the epoxide (17).  
 
Scheme 3.4. Attempt to synthesize C5’-C6’ epoxide. 
After trying different condition, only trace amounts of the desired product (17) were 
obtained. The by-product could not be characterized as the reaction was messy. The only 
insight we had was that there was a consistent peak in the mass spectrometry that was 
approximately 14 units more than the desired product. It led us to think, though unlikely, 
that the C=O moiety of the –NHCOPh at the C6 might be reacting. So the benzoyl group 
was removed from the C6-amino position and it (18, Scheme 5) was then subjected to the 
trimethylsilyl diazomethane. The reaction was still messy and the product could not be 
isolated. However, the mass spectrometry confirmed the starting material was consumed 
and the desired product (20) was present. The crude mixture was allowed to react with 
NaI to install the iodo-group at C6’-position (21). We always recovered back the starting 
material. Mildly acidic conditions, which are supposed to open the epoxide in the 
undesired way, were also employed but we did not see any conversion. These results 
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were puzzling. The problem could not be solved, so instead we took an alternative route 
(Scheme 6).  
 
 
Scheme 3.5. Attempt to open the epoxide.  
 
In this route instead of introducing the extra carbon via diazomethane reagent, we 
decided to use a Witting reaction. Similar reaction conditions were applied to both 16 and 
19. It was found that the yield from 16 was better. Moreover, we needed the benzoyl 
group at C6-amino position for DNA synthesis. So we decided to move forward using 16. 
 
Scheme 3.6: Synthesis of precursor to the iodination at C6’ position 
To regenerate the hydroxyl group at C5’-position, an Upjohn dihydroxylation reaction16 
was performed with 22 to generate 23. This reaction generated two diastereomers at C5’ 
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position. However, they were inseparable by column chromatography. So the mixture 
was moved forward according to the scheme. To connect the C6’ of the sugar with the C8 
of the purine, we needed an iodo-group at C6’-position. For that, the 6’-OH needed to be 
converted to a better leaving group. It was achieved by reacting 23 with p-TsCl. We 
obtained the two diastereomers (24a and 24b) and the di-tosylated products in the ratio of 
1:1:0.2. Those were separated at this stage. Each of the diastereomers were refluxed in 
acetone with NaI to derive the desired iodo-compound (25a and 25b).   
 
Scheme 3.7: Installing the iodo-group at C6’ of both the diastereomers. 
The next step is cyclization. Two different methodologies were tried. In the first 
procedure, the iodo-compound was treated with AIBN and Bu3SnH in refluxing 
condition. This resulted in either no product or very trace amount of product. It was not 
viable considering it is deep in the synthesis scheme. The second procedure is to reflux 
the iodo-compound with Zn. Similar conditions resulted in reasonable yields for the 8,5-
(S)-cyclo-2’-deoxyguanosine discussed in section 3.2. But with 25, the results are not 
encouraging yet. I had to stop at this point because I was running out of material. One of 
my coworkers, Han Yueh, is collaborating with me in this project and trying to optimize 
the step.  
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3.4. Experimental and Methods 
In Reference to section 3.2. 
Compound 4: The compound 3 (4.9 g, 10 mmol), imidazole (2.03 g, 30 mmol), and silver 
nitrate (5.50 g, 30 mmol) were dissolved in dry pyridine (100 mL) and cooled to 0 ᵒC.  
Triisopropylsilyl chloride (6.3 ml, 30 mmol) was added and the reaction was warmed to 
ambient temperature. After stirring for 3 days the reaction, the starting material was 
consumed. The reaction was cooled to 0 ᵒC in ice-bath and quenched with water. The 
solvents were removed under reduced pressure and the residue dissolved in 
dichloromethane and washed with water three times.  The organic layer was dried over 
sodium sulfate and concentrated under vacuum.  The crude product was purified by flash 
chromatography (1:49 MeOH:DCM) to yield compound 4 (4.56 g, 71%). Rf = 0.49 (1:49 
MeOH:DCM). 1H NMR (500 MHz, CDCl3) δ 12.07 (s, 1H), 9.16 (s, 1H), 7.75 (d, J = 8.3 
Hz, 2H), 7.69 (s, 1H), 7.35 (d, J = 8.3 Hz, 2H), 6.13 (dt, J = 8.8, 4.4 Hz, 1H), 4.56 – 4.47 
(m, 2H), 4.13 (tdd, J = 9.3, 6.3, 3.4 Hz, 2H), 3.30 – 3.21 (m, 1H), 2.64 (dt, J = 13.7, 6.9 
Hz, 1H), 2.45 (s, 3H), 2.21 (td, J = 14.1, 6.2 Hz, 1H), 1.24 (dd, J = 8.3, 4.8 Hz, 3H), 1.20 
(d, J = 6.8 Hz, 3H), 1.10 – 1.04 (m, 3H), 1.04 – 0.94 (m, 18H). 13C NMR (126 MHz, 
CDCl3) δ 179.16, 155.66, 148.07, 147.41, 145.86, 139.27, 132.08, 130.30, 127.85, 
123.17, 86.78, 85.42, 73.41, 69.04, 39.23, 36.42, 21.82, 19.12, 18.96, 18.84, 18.10, 18.01, 
17.68, 17.14, 13.72, 12.56, 12.14, 12.03. HRMS (ESI-TOF) calcd for [M + Na]+ 
670.27011, found: 670.27050. 
Compound 5: Compound 4 (4.25 g, 6.56 mmol) and sodium iodide (3.93 g, 26.24 mmol) 
were dissolved in dry acetone (65 mL) and refluxed for 8 hours. The solid suspension 
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was filtered through celite and the filtrate was concentrated under vacuum. The crude was 
purified by flash chromatography (1.5:98.5 MeOH:DCM) to yield compound 5 as a white 
foam (3.72 g, 94%). Rf = 0.44 (1:49 MeOH:DCM). 
1H NMR (500 MHz, CDCl3) δ 12.38 
(s, 1H), 10.54 (s, 1H), 7.87 (s, 1H), 6.22 – 6.15 (m, 1H), 4.47 (ddt, J = 26.1, 5.6, 2.7 Hz, 
1H), 3.99 – 3.91 (m, 1H), 3.42 – 3.29 (m, 2H), 3.03 – 2.90 (m, 1H), 2.84 (ddt, J = 13.7, 
10.7, 6.7 Hz, 1H), 2.36 – 2.27 (m, 1H), 1.20 (d, J = 6.8 Hz, 3H), 1.16 (dt, J = 9.4, 4.7 Hz, 
3H), 1.09 – 0.93 (m, 21H). 13C NMR (126 MHz, CDCl3) δ 179.96, 156.06, 148.73, 
148.12, 138.19, 121.79, 86.78, 84.95, 75.49, 39.62, 36.06, 19.18, 19.05, 18.82, 18.09, 
18.05, 17.68, 17.11, 13.91, 12.58, 12.11, 6.95. HRMS (ESI-TOF) calcd for [M + H]+ 
604.18160, found: 604.18230. 
Compound 7: Compound 5 (3.5 g, 5.80 mmol) and zinc powder (7.6 g, 116 mmol) were 
mixed in anhydrous pyridine (125 mL) and heated to 60 ᵒC for 6 hours. The zinc powder 
was removed by filtration through celite and the filtrate was concentrated under reduced 
pressure. The residue and tetrachloro-1,4-benzoquinone (1.43 g, 5.80 mmol) were mixed 
in anhydrous benzene (100 mL) and refluxed for 4 hours. The solvent was then 
evaporated under vacuum and the crude product was purified by flash chromatography 
(1:49 MeOH:DCM) to yield the cyclized product as a light yellowish white foam (1.27 g, 
46%).  Rf : 0.29 (3:97 MeOH:DCM). 
1H NMR (500 MHz, CDCl3) δ 12.04 (s, 1H), 8.98 
(s, 1H), 6.28 (d, J = 5.0 Hz, 1H), 4.71 (t, J = 7.5 Hz, 1H), 4.48 (dd, J = 7.0, 3.6 Hz, 1H), 
3.43 (dd, J = 17.6, 6.1 Hz, 1H), 2.95 (d, J = 17.5 Hz, 1H), 2.69 (dq, J = 13.4, 6.7 Hz, 1H), 
2.56 (dd, J = 13.4, 7.1 Hz, 1H), 2.25 (ddd, J = 16.5, 10.5, 6.2 Hz, 1H), 1.27 (d, J = 3.9 Hz, 
3H), 1.25 (d, J = 3.9 Hz, 3H), 1.10 – 1.05 (m, 3H), 1.05 – 0.99 (m, 18H). 13C NMR (126 
MHz, CDCl3) δ 178.69, 155.31, 147.42, 145.91, 142.26, 120.37, 84.66, 83.57, 75.47, 
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48.31, 36.59, 30.76, 29.82, 19.20, 19.02, 17.99, 17.96, 11.96. HRMS (DART-TOF) calcd 
for [M + H]+ 476.27096, found: 476.26930. 
Compound 8: Compound 7 (1.0 g, 2.11 mmol) and selenium dioxide (482 mg, 4.35 
mmol) were taken in 1,4-dioxane (250 mL) and refluxed for 2 hour. The reaction mixture 
was filtered through celite and the solvent removed under vacuum.  The product was 
purified by flash chromatography (1:24 MeOH:DCM) to yield 8 as a reddish white foam 
(769 mg, 78%).  Rf : 0.21 (1:24 MeOH:DCM). 
1H NMR (500 MHz, CDCl3) δ 11.98 (s, 
1H), 8.39 (s, 1H), 6.48 (d, J = 5.4 Hz, 1H), 4.88 (dd, J = 7.0, 2.8 Hz, 1H), 4.83 (s, 1H), 
2.83 (dd, J = 13.9, 7.0 Hz, 1H), 2.68 (dt, J = 13.8, 6.9 Hz, 1H), 2.46 (ddd, J = 13.8, 5.6, 
2.5 Hz, 1H), 1.65 (s, 3H), 1.31 (t, J = 6.9 Hz, 6H), 1.20 – 1.12 (m, 3H), 1.11 – 1.05 (m, 
18H). 13C NMR (126 MHz, CDCl3) δ 183.08, 178.64, 155.37, 149.63, 145.65, 138.56, 
123.09, 92.38, 85.63, 72.86, 44.98, 36.87, 19.06, 18.98, 17.99, 11.97. HRMS (DART-
TOF) calcd for [M + H]+ 490.24857, found: 490.24853. 
Compound 9: Compound 8 (0.50 g, 1.02 mmol) was dissolved in methanol (30 mL) and 
cooled to 0 ᵒC, 0.1 M sodium borohydride aqueous solution (5.75 mL) was added and the 
stirring reaction was allowed to warm to ambient temperature.  After 45 min the reaction 
was neutralized with 1(N) hydrochloric acid and the solvents were removed under 
vacuum.  The crude product was purified by flash chromatography (3.5:96.5 
MeOH:DCM) to yield 9 as a white powder (0.453 g, 95%).  Rf: 0.27 (3:97 MeOH:DCM). 
1H NMR (500 MHz, CDCl3) δ 12.24 (s, 1H), 9.87 (s, 1H), 6.34 (d, J = 4.9 Hz, 1H), 5.30 
(d, J = 6.3 Hz, 1H), 4.99 (dd, J = 7.0, 3.8 Hz, 1H), 4.77 (d, J = 6.4 Hz, 1H), 2.79 (dt, J = 
13.8, 6.9 Hz, 1H), 2.58 (dd, J = 13.4, 7.2 Hz, 1H), 2.30 – 2.22 (m, 1H), 1.25 (t, J = 6.1 
Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 1.08 (td, J = 7.5, 3.5 Hz, 3H), 1.06 – 0.98 (m, 18H). 
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13C NMR (126 MHz, CDCl3) δ 179.26, 155.13, 148.18, 147.25, 145.42, 120.10, 86.48, 
85.22, 69.29, 64.07, 46.95, 36.15, 19.09, 18.84, 17.84, 17.83, 11.85. HRMS (DART-
TOF) calcd for [M + H]+ 492.2642, found: 492.26368. 
Compound 10: Compound 9 (0.083 g, 0.17 mmol) and pyridinium-p-toluenesulfonate (47 
mg, 0.19 mmole) were dissolved in dichloromethane (1.7 mL) followed by the addition 
of ethyl vinyl ether (0.1 mL, 1.02 mmol) and stirred overnight at ambient temperature. 
The solvents were removed under vacuum and the crude product was purified by flash 
chromatography (3:97 MeOH:DCM) to yield 10 as a light yellowish white foam (0.085 g, 
89%). Rf = 0.32 (silica gel, 3:97 MeOH:DCM)). 
1H NMR (500 MHz, CDCl3) δ 12.14 (s, 
2H), 9.37 (s, 2H), 6.26 (dd, J = 6.3, 5.1 Hz, 2H), 5.56 (q, J = 5.2 Hz, 1H), 5.26 – 5.19 (m, 
2H), 5.12 (d, J = 6.2 Hz, 1H), 4.93 (tdd, J = 12.1, 7.6, 4.5 Hz, 2H), 4.66 (d, J = 6.4 Hz, 
1H), 4.60 (d, J = 6.2 Hz, 1H), 3.78 (dq, J = 9.4, 7.1 Hz, 1H), 3.72 – 3.65 (m, 2H), 3.62 – 
3.55 (m, 1H), 2.81 – 2.72 (m, 2H), 2.49 (ddd, J = 13.1, 7.2, 3.2 Hz, 2H), 2.25 – 2.17 (m, 
2H), 1.47 (d, J = 5.3 Hz, 3H), 1.33 (t, J = 4.8 Hz, 3H), 1.28 – 1.22 (m, 12H), 1.21 – 1.13 
(m, 6H), 1.12 – 0.96 (m, 42H). HRMS (DART-TOF) calcd for [M + H]+ 564.32173, 
found: 564.32045. 
Compound 11: Tetra-n-butylammonium fluoride (1.0 M solution in THF, 0.29 mL) was 
added to a solution of 10 (0.075 g, 0.133 mmol) in THF (8.5 mL) at ambient temperature 
and stirred for one hour. The solvent was removed under reduced pressure. The crude 
material was dissolved in acetonitrile (3.6 mL).  1H-tetrazole in acetonitrile (0.45 M 
solution in MeCN, 0.12 mL) was added followed by 2-cyanoethyl N,N,N',N'-
tetraisopropyl phosphorodiamidite (36 μL, 0.109 mmol) and the mixture was stirred 
overnight at ambient temperature. The reaction was quenched with 5% trietheylamine in 
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methanol and the solvents were removed under vacuum.  The residue was dissolved in 
DCM and washed with saturated sodium bicarbonate three times and once with brine. 
The organic layer was dried over sodium sulfate. After removing the sodium sulfate, 
hexanes were added to effect precipitation. The precipitate was collected by filtration and 
washed with hexanes several times. The precipitate was purified by flash chromatography 
(0.1:0.9:99 Et3N:MeOH:DCM) to yield compound 11 as a white powder in quantitative 
yield (53 mg, 65% over two steps). 31P NMR (202 MHz, CDCl3) δ 148.93, 148.85, 
148.53, 148.34. HRMS (ESI-TOF) calcd for [M + H]+ 608.29561, found: 608.29600. 
 
DNA Synthesis 
The native and modified 12-mers (entry 1-4, Table 1) were prepared by solid-phase DNA 
synthesis and deprotected using standard protocols. The analogue nucleotides could be 
incorporated into DNA strands with essentially the same coupling efficiency as the 
common nucleotides using the wait time of 20 min during the coupling cycle. All newly-
synthesized oligonucleotides were deprotected and cleaved from the CPG beads by 12–
14 hr treatment with concentrated ammonia at 55 °C. The supernatant solutions were then 
decanted and evaporated under high vacuum, then redissolved in 12-15 mL H2O for 
HPLC purification. 
 
Initial purification of native and modified oligonucleotides was accomplished by HPLC 
(Oligo R3 reverse-phase C18 column, trityl on), starting with 100% solution A using a 
linear gradient from 0 to 65% solution B over 20 min [solution A:  1 M TEAA (pH 7) in 
5% acetonitrile; solution B: 1 M TEAA (pH 7) in 70% acetonitrile]. The DMT-protected 
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12-mers had retention times of about 17.5 minutes, except for Sequence 1, which had a 
retention time of 8.5 min due to the presence of a EVE group at the terminal nucleoside 
(instead of DMTr-group). The collected oligonucleotides were then reduced in volume 
and detritylated using 80% acetic acid for 30 min at 0 °C. The resulting oligonucleotides 
were then desalted and lyophilized.  
HPLC traces of DNA (Entry 1, 2, 3 and 4 from Table 3.1) are below. 
 
DNA 1 
 
DNA 2 
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DNA 3 
 
DNA 4 
 
 
In Reference to section 3.3. 
Compound 14: Compound 13 (9.5 g, 14.44 mmol), imidazole (2.95g, 43.32 mmol) and 
AgNO3 (7.36 g, 43.32 mmol) were taken in pyridine (75 mL). The mixture was cooled to 
0 ᵒC. To this, TIPSCl (9.2 mL, 43.32 mmol) was added dropwise and the temperature 
was allowed to warm up to room temperature. The reaction mixture was stirred for 3 days 
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at ambient temperature. Water was added to quench the reaction followed by removal of 
the solvent under high vacuum. The crude was dissolved in chloroform and washed with 
water. The organic layer was collected, dried over anhydrous Na2SO4, filtered and the 
filtrate was concentrated in vacuo. It was purified by flash column chromatography 
(0.1:1.5:98.5 TEA:MeOH:DCM) to yield compound 14 (10.11 g, 86%). Rf = 0.34 (1:49 
MeOH:DCM). 1H NMR (500 MHz, CDCl3) δ 9.32 (s, 1H), 8.72 (s, 1H), 8.21 (s, 1H), 
8.03 - 7.99 (m, 2H), 7.57- 7.52 (m, 1H), 7.48 -7.44 (m, 2H), 7.39 (dt, J = 8.5, 1.9 Hz, 
2H), 7.31 - 7.27 (m, 4H), 7.24 (ddd, J = 8.4, 3.2, 1.7 Hz, 2H), 7.20 - 7.17 (m, 1H), 6.81 - 
6.76 (m, 4H), 6.50 (dt, J = 12.2, 6.1 Hz, 1H), 4.69 (dt, J = 5.4, 2.8 Hz, 1H), 4.22 (td, J = 
4.4, 2.8 Hz, 1H), 3.75 (s, 6H), 3.44 (dd, J = 10.4, 4.5 Hz, 1H), 3.32 (dd, J = 10.4, 4.4 Hz, 
1H), 2.84 (ddd, J = 13.0, 7.4, 5.6 Hz, 1H), 2.52 (ddd, J = 13.0, 6.0, 2.9 Hz, 1H), 1.08 - 
0.99 (m, 21H); 13C NMR (126 MHz, CDCl3) δ 164.72, 158.54, 152.51, 151.52, 149.53, 
144.49, 141.65, 135.67, 135.63, 133.73, 132.64, 130.01, 129.99, 128.76, 128.10, 127.87, 
127.82, 126.87, 123.59, 113.12, 87.50, 86.56, 85.01, 73.16, 63.52, 55.19, 41.03, 17.98, 
12.05. HRMS (ESI-TOF) calcd for [M + H]+ 814.3994, found: 814.4000. 
Compound 15: Compound 14 (10.00 g, 12.28 mmol) was dissolved in DCM (120 mL) 
and cooled to 0 ᵒC. A solution of p-TsOH (5.19 g, 27.02 mmol) in methanol (30 mL) was 
added dropwise. It was stirred at 0 ᵒC for 30 min. The TLC indicated the complete 
consumption of compound 2. The reaction was quenched with satd. aq. NaHCO3 
solution. DCM was added to the solution and was washed by water. The organic layer 
was collected, dried over anhydrous Na2SO4, filtered and the filtrate was concentrated in 
vacuo. It was purified by flash column chromatography (3:97 MeOH:DCM) to yield 
compound 15 (5.34 g, 85%). Rf = 0.24 (1:49 MeOH:DCM). 1H NMR (500 MHz, CDCl3) 
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δ 9.47 (s, 1H), 8.69 (s, 1H), 8.09 (s, 1H), 8.00 - 7.96 (m, 2H), 7.56 - 7.51 (m, 1H), 7.47 - 
7.42 (m, 2H), 6.35 (dd, J = 9.4, 5.4 Hz, 1H), 4.75 (d, J = 4.8 Hz, 1H), 4.17 (d, J = 0.7 Hz, 
1H), 3.93 (dd, J = 12.8, 1.6 Hz, 1H), 3.74 (d, J = 8.6 Hz, 1H), 3.00 (ddd, J = 13.0, 9.4, 5.0 
Hz, 1H), 2.29 (dd, J = 12.4, 5.6 Hz, 1H), 1.11 - 1.01 (m, 21H); 13C NMR (126 MHz, 
CDCl3) δ 164.82, 152.02, 150.78, 150.29, 142.64, 133.53, 132.79, 128.76, 128.00, 
124.50, 90.53, 87.67, 74.10, 63.25, 41.76, 17.96, 11.97. HRMS (ESI-TOF) calcd for [M 
+ H]+ 512.2688, found: 512.2693. 
Compound 16: Compound 15 (5.25 g, 10.26 mmol) and solid DMP (6.53 g, 15.39 mmol) 
were taken in DCM (150 mL) and stirred for 2.5 hrs at ambient temperature. The reaction 
was quenched by a 1:1 mixture of satd. aq. solution of Na2S2O3 and NaHCO3. DCM was 
added to the solution and was washed by water. The organic layer was collected, dried 
over anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuo to yield the 
crude compound 16. The crude was used in the next step. 
Compound 22: CH3PPh3Br (11 g, 30.78 mmol) and 
tBuOK (3.45 g, 30.78 mmol) were 
suspended in THF (150 mL). It was stirred at ambient temperature for an hour. A solution 
of the crude compound 16, from previous step, in THF (37 mL) was added slowly to the 
reaction mixture. It was allowed to stir for another 5 hrs. The reaction was quenched by 
satd. aq. solution of NH4Cl. Solvent was removed in vacuo. The crude was dissolved in 
DCM and washed with water. The organic layer was collected, dried over anhydrous 
Na2SO4, filtered and the filtrate was concentrated. It was purified by flash column 
chromatography (11:9 EtOAc:Hex) to yield compound 22 (2.76 g, 53% over two steps). 
Rf = 0.23 (1:19 MeOH:DCM). 
1H NMR (400 MHz, CDCl3) δ 9.31 (s, 1H), 8.75 (s, 1H), 
8.16 – 7.97 (m, 2H), 7.60 – 7.44 (m, 3H), 6.47 (d, J = 2.8 Hz, 1H), 6.05 – 5.91 (m, 1H), 
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5.34 (d, J = 17.1 Hz, 1H), 5.27 – 5.20 (m, 1H), 4.60 (d, J = 2.2 Hz, 1H), 4.47 (s, 1H), 2.87 
(dd, J = 5.6, 2.4 Hz, 1H), 2.58 – 2.48 (m, 1H), 1.20 (dd, J = 21.0, 18.2 Hz, 3H), 1.12 – 
0.98 (m, 18H). 13C NMR (101 MHz, CDCl3) δ 164.86, 152.66, 151.69, 149.68, 141.81, 
135.67, 133.73, 132.80, 128.87, 128.00, 123.86, 118.18, 89.06, 85.04, 76.14, 40.34, 
29.36, 18.04, 12.12. HRMS (ESI-TOF) calcd for [M + H]+ 508.2744, found: 508.2730. 
Compound 23: Compound 22 (2.5 g, 4.92 mmol) and NMO (1.47 g, 12.55 mmol) were 
taken in DCM (125 mL). To this 2% aq. solution of OsO4 (0.13 mL, 0.01 mmol) was 
added. The reaction was allowed to stir for 10 hrs at ambient temperature. The reaction 
was quenched with satd. aq. solution of Na2S2O3. DCM was added to the solution and 
was washed by water. The organic layer was collected, dried over anhydrous Na2SO4, 
filtered and the filtrate was concentrated in vacuo. It was purified by flash column 
chromatography (1:24 MeOH:DCM) to yield compound 23 (1.79 g, 67%). Rf = 0.31 
(1:19 MeOH:DCM). HRMS (ESI-TOF) calcd for [M + H]+ 542.28010, found: 
542.279322. 
Compound 24: Compound 23 (1.70 g, 3.14 mmol) and DMAP (704 mg, 6.28 mmol) were 
dissolved in DCM (30 mL) and it was cooled to 0 ᵒC. A solution of p-TsCl (659 mg, 3.45 
mmol) in DCM (10 mL) was added to the reaction mixture using a dropping funnel. It 
was slowly allowed to warm to room temperature. The reaction mixture was stirred for 
20 hrs at ambient temperature. DCM was added to the solution and was washed by water. 
The organic layer was collected, dried over anhydrous Na2SO4, filtered and the filtrate 
was concentrated in vacuo. It was purified by gravity column chromatography (1.5:98.5 
MeOH:DCM) to yield two diastereomers of compound 24- 24a (787 mg, 36%) and 24b 
(764 mg, 35%). Rf of 24a (the higher spot on TLC) = 0.49 (1:19 MeOH:DCM). Rf of 24b 
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(the lower spot on TLC) = 0.47 (1:19 MeOH:DCM). Characterization of compound 24a: 
1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 8.08 (s, 1H), 8.02 (dt, J = 3.3, 2.4 Hz, 2H), 
7.76 – 7.73 (m, 2H), 7.64 – 7.60 (m, 1H), 7.55 – 7.51 (m, 2H), 7.28 (dd, J = 8.6, 0.6 Hz, 
2H), 6.35 – 6.32 (m, 1H), 4.76 (d, J = 4.7 Hz, 1H), 4.26 (s, 1H), 4.02 (t, J = 11.6 Hz, 3H), 
2.96 (ddd, J = 13.1, 9.8, 5.0 Hz, 1H), 2.42 (s, 3H), 2.32 – 2.27 (m, 1H), 1.15 – 1.09 (m, 
3H), 1.09 – 1.06 (m, 18H). 13C NMR (126 MHz, CDCl3) δ 164.63, 151.92, 150.51, 
145.00, 142.63, 133.49, 133.13, 132.94, 129.92, 129.07, 128.05, 124.71, 88.78, 88.20, 
74.93, 70.02, 69.89, 41.41, 29.41, 21.77, 18.09, 18.09, 12.05. HRMS (ESI-TOF) calcd for 
[M + H]+ 696.288172, found: 696.28870. Characterization of compound 24b: 1H NMR 
(500 MHz, CDCl3) δ 8.71 (s, 1H), 8.08 (s, 1H), 8.04 – 7.99 (m, 2H), 7.82 – 7.78 (m, 2H), 
7.64 – 7.59 (m, 1H), 7.55 – 7.50 (m, 2H), 7.36 – 7.32 (m, 2H), 6.32 (dd, J = 9.6, 5.4 Hz, 
1H), 4.77 (d, J = 4.3 Hz, 1H), 4.19 – 4.09 (m, 4H), 3.07 (ddd, J = 13.1, 9.7, 4.6 Hz, 1H), 
2.44 (s, 3H), 2.31 (dd, J = 12.9, 5.6 Hz, 1H), 1.13 – 1.03 (m, 21H). 13C NMR (126 MHz, 
CDCl3) δ 164.60, 152.18, 150.72, 150.41, 145.19, 142.88, 133.59, 133.08, 132.75, 
130.03, 129.05, 128.18, 128.02, 124.65, 90.02, 87.46, 72.89, 70.22, 70.17, 41.14, 29.41, 
21.79, 18.15, 12.22. HRMS (ESI-TOF) calcd for [M + H]+ 696.288172, found: 
696.28950. 
Compound 25: Both the epimers, 24a (higher spot) and 24b (lower spot) were treated 
with NaI (5 eqvt.) in anhydrous acetone (0.1 M reaction concentration with respect to the 
starting material) in refluxing condition for 12 hrs. The TLC indicated the complete 
consumption of the starting material. The reaction mixture was filtered through celite to 
remove excess NaI. The filtrate was concentrated in vacuo and purified by flash column 
chromatography. Yield 25a and 25b was 89% and 86% respectively. Characterization of 
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compound 25a: 1H NMR (500 MHz, CDCl3) δ 8.76 – 8.73 (m, 1H), 8.10 (s, 1H), 8.02 (dt, 
J = 8.5, 1.6 Hz, 2H), 7.64 – 7.59 (m, 1H), 7.53 (dt, J = 7.3, 1.7 Hz, 2H), 6.39 (dd, J = 9.8, 
5.3 Hz, 1H), 4.74 (d, J = 4.7 Hz, 1H), 4.65 (s, 1H), 3.98 (d, J = 5.1 Hz, 1H), 3.28 (dd, J = 
9.7, 5.6 Hz, 1H), 3.18 (t, J = 9.6 Hz, 1H), 3.05 (ddd, J = 13.0, 9.9, 5.0 Hz, 1H), 2.29 (dd, J 
= 13.0, 5.4 Hz, 1H), 1.19 – 1.12 (m, 3H), 1.12 – 1.07 (m, 18H). 13C NMR (126 MHz, 
CDCl3) δ 164.61, 151.94, 150.59, 150.56, 142.78, 133.51, 133.13, 129.07, 128.03, 
124.82, 89.17, 88.26, 75.57, 72.86, 41.14, 18.13, 12.10, 6.32. HRMS (ESI-TOF) calcd for 
[M + H]+ 652.1816, found: 652.1819. Characterization of compound 25b: 1H NMR (500 
MHz, CDCl3) δ 8.78 (s, 1H), 8.09 (s, 1H), 8.04 – 8.00 (m, 2H), 7.64 – 7.59 (m, 1H), 7.56 
– 7.50 (m, 2H), 6.34 (dd, J = 9.7, 5.4 Hz, 1H), 4.79 (d, J = 4.4 Hz, 1H), 4.27 (d, J = 3.1 
Hz, 1H), 4.09 (td, J = 8.0, 3.0 Hz, 1H), 3.29 (qd, J = 10.3, 6.4 Hz, 2H), 3.14 (ddd, J = 
13.1, 9.8, 4.7 Hz, 1H), 2.32 (dd, J = 13.0, 5.5 Hz, 1H), 1.14 (ddd, J = 10.3, 7.2, 4.0 Hz, 
3H), 1.10 (dd, J = 6.8, 3.9 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ 164.58, 152.30, 
150.82, 150.31, 142.90, 133.59, 133.07, 129.06, 128.02, 124.76, 91.26, 87.54, 72.79, 
72.67, 41.15, 18.19, 12.29, 6.83. HRMS (ESI-TOF) calcd for [M + H]+ 652.1816, found: 
652.1841. 
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Background 
Over the last two decades, there has been a huge interest in the field of nucleic acid based 
technologies for genome analyses, diagnostics and therapeutics. It gained even more 
momentum after the projection of the Human Genome Project (HGP) in 1990 by the U.S. 
Department of Energy and the National Institutes of Health. During the early years of the 
HGP, the Wellcome Trust (U.K.) became a major partner; additional contributions came 
from Japan, France, Germany, China, and others. Though the HGP is finished, analyses 
of the data will continue for many years1. The completion of this project will effect a 
revolution in biomedical sciences and related industries. In particular, tailor-made 
medications, molecular targeted therapies, and genetic medicines based on human 
genomic information are attracting much attention worldwide2. Among them, antigene 
strategy is one promising technology to regulate gene expression in living cells. There are 
issues, limitations, roadblocks but, still, significant progress has been made. Hopefully, 
this technology will be the answer to a number of disease-curing and biomedical 
problems. 
Conceptually, there are two major ways an agent can bind to a DNA duplex: from outside 
and by invading the DNA duplex. Agents like triplex forming oligonucleotides (TFOs) 
bind externally in the major groove of duplex DNA with high specificity and affinity3. 
On the other hand, peptide nucleic acids (PNA) are known to invade the DNA duplex and 
form triplexes; thereby interfere with transcription internally4. In the next section we will 
discuss various aspects of TFOs. The goal of my third project is to target DNA duplex 
sequence specifically using PNA employing a fundamentally new approach, the Janus 
Wedge format.  
152 
 
4.1. Triplex Forming Oligonucleotides 
4.1.1. Types of triplexes 
The fact that nucleic acid can form a triplex structure was observed in 19575 and the 
mode of nucleobase triads was experimentally determined by Hoogsteen6. Regardless of 
the specificity that can be achieved, triplex formation is restricted to DNA duplexes with 
poly-purine on one strand and pyrimidines on the other. Substantial effort has been 
expended in the study of the triplex binding code. Though it was initially observed that 
only the purine oligonucleotides could bind their target under physiologic conditions 
(most notably neutral pH) the advancement of base substitution technology has allowed 
the engineering of pyrimidine TFOs which can also bind effectively under physiologic 
conditions7.  
In depth research revealed that the triplexes can be divided into two types: parallel and 
antiparallel8. In the parallel motif triplex, the third strand is a homopyrimidine sequence. 
This third strand and the Pu strand of DNA duplex are in a parallel orientation. The base 
triads form Hoogsteen hydrogen bondings in the parallel motif triplex (Figure 4.1.A.). On 
the other hand, the antiparallel-type triplex has the third strand with a homopurine 
sequence. This third strand and the Py strand of the duplex are in an antiparallel 
orientation. The base triads have reverse-Hoogsteen hydrogen bondings (Figure 4.1.B.). 
Of the two triplex motifs, most of the focus was on the parallel motif, in which tuning the 
properties of the external strand by an appropriate chemical modification is less 
complicated9. 
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Figure 4.1. Schematic illuatration of- A. parallel motif triplex and structure of Hoogsteen 
Base Triads B. anti-parallel motif triplex and structure of Reverse-Hoogsteen Base 
Triads. 
 
4.1.2. Limitations of TFOs 
Although there has been significant progress in using TFOs for regulating transcription, 
there are a few limitations that appear to be major roadblock for its application as 
therapeutics. Some of these limitations are mentioned below: 
 To form a stable triplex, a homopurine–homopyrimidine tract is required in the 
target duplex. It also signifies that mixed sequences cannot be targeted. The 
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occurrence of such unique stretch of polypurines is rare. Hence its applicability is 
limited. 
 Both Hoogsteen and reverse-Hoogsteen triads have only two hydrogen bondings, 
while the Watson–Crick base pairs have two or three hydrogen bondings. This 
results in low stability of the triplex structure.  
 The cytosine in a parallel motif TFO must be protonated at its N3 position to 
form a stable nucleobase triad C+∗GC (in which ∗ means Hoogsteen bonds). This 
signifies that the stability of a parallel motif triplex drastically decreases under 
neutral or basic conditions, although it is reasonably stable under acidic 
conditions. 
 Physiologic potassium concentrations can inhibit binding in particularly G-rich 
TFOs. Under this condition, G quartets and other secondary structures within the 
oligonucleotides are favored10. This has been addressed with a variety of 
chemical substitutions. Replacement of natural bases with modified bases such as 
6-thioguanine11  or 7-deazaxanthine12 has addressed the problem to some extent. 
In the next section we will discuss about a relatively new approach of triplex formation 
using Janus Wedge triplexes. 
4.2. Janus Wedge (Jw) Triplexes 
The most of the success with PNA mediated DNA duplex binding relied primarily on the 
triplex invasion mechanism (Figure 1.20). One of the PNA strands binds with one of the 
DNA strands of the duplex from the Watson-Crick face and the other PNA strand binds 
the same DNA strand from the Hoogsteen face (the two PNA strands may be a part of 
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bis-PNA molecule). As in the case of TFO, a major concern is to have a polypurine 
stretch in the DNA strand and it mostly fails with a mixed sequence. 
This led us to think about alternative approaches. The challenge was can we actually 
invade the DNA duplex and form a DNA-PNA-DNA triplex. If we can prepare the PNA 
strand by tethering unnatural bases with proper hydrogen bonding forming profile that 
can actually differentiate A-T, T-A, G-C and C-G, then we can potentially achieve our 
goal to target any part of the DNA duplex. The success of this new approach will provide 
a one-residue to one-base-pair targeting format for the recognition of all four DNA base 
pairs, and thus provide a motif for generalizing the process of DNA duplex recognition 
using the triple helix format.      
In our approach of Jw triplexes, a third strand of DNA (or PNA) inserts itself between the 
two Watson-Crick faces of the base pairs of the duplex to result in a new type of DNA 
triplex.  These triplexes are termed Janus Wedge triplexes13 after the Roman god Janus.  
Janus stood for the beginning of everything, guardian of heaven and of all gates and 
doors.  Janus is typically pictured with two faces, supposedly so he could see what was 
coming and going.  The Jw residue in the Janus Wedge triplex, contains two hydrogen 
bonding faces such that after insertion into the DNA duplex, the Jw residue is hydrogen-
bonded to both Watson-Crick faces of the target base pair.  Both pyrimidine-like (Figure 
4.2, left) and purine-like (Figure 4.2, right) residues can be used in this design.   
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Figure 4.2. Schematic representation of pyrimidine (left) and purine (right) like Jw bases. 
The Jw triplexes are envisioned as thermodynamically favorable over the DNA duplex 
because: 
 Three-stranded complexes contain significantly more interstrand hydrogen bonds 
than the DNA duplexes. So the triplex structure should be stable. 
 Enhanced base stacking between the consecutive triplex layers, because of the 
isomorphic structures, should also contribute to the stability of the triplex 
structure (Figure 4.3).  
 
Figure 4.3. Enhanced base stacking between the triplex layers. 
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To investigate the potentiality of this approach, we need two components to prepare these 
agents: 
 Backbone- For this approach we need a backbone that can approach the DNA 
duplex and invade it. As we have discussed, because of their neutral backbone 
and ability of invading duplex, PNA is the first choice as backbone of these 
agents. Other backbones will also be considered, but our initial focus is the PNA 
oligomer.  Other possible backbones include the methylphosphonate linkage 
(linking 2’-deoxynucleosides) that should limit charge-charge effects and may 
facilitate strand invasion. 
 Unnatural nucleobase- The base should have two hydrogen bond forming faces 
with proper hydrogen donor-acceptor profile. This cannot be achieved by the 
natural bases. So we need to design these bases. Generation 1 bases, developed in 
our laboratory, are pyrimidine-like and Generation 2 bases are purine-like.  
The PNA stand competes with and displaces the pyrimidine strand at oligopurine sites to 
form a D-loop structure consisting of a PNA-DNA (purine) duplex with a displaced DNA 
(pyrimidine) strand (Figure 4.4)14.  A second PNA then binds to this initially formed 
duplex and results in a PNA-DNA-PNA triplex.  We expect that the PNA Jw strand also 
binds by a strand invasion mechanism since it is designed to be complementary to the 
target residues, but since the second face of the Jw residue is complementary to the 
displaced strand, the Jw triplex results.  This process can be further explored with a target 
sequence of oligo A-oligo T within a native duplex. The dA-dT base pairs have only 2 
hydrogen bonds to disrupt, and they are more susceptible to base pair disruption15. 
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Figure 4.4. Strand invasion by a PNA to form initially the D-Loop structure, followed by 
a PNA-DNA-PNA triplex, or Jw triplex, depending upon the choice of the PNA strand. 
 
Previously, our lab prepared the Generation 1 Janus-Wedge (Jw) residues. One of them is 
called W1 and it targets A-T and T-A
16, whereas other is called W2
17 and it targets G-C 
and C-G. The designs of these residues are presented in Figure 4.5. 
 
Figure 4.5. Design of Generation 1 Jw residues. Left- W1 to target A-T and T-A; Right- 
W2 to target G-C and C-G.  
These bases were introduced in DNA and biophysical studies were done. The results 
were encouraging. Below are the results found from those studies: 
 Thermal denaturation studies: The thermal denaturation studies showed that these 
Jw triplexes showed two transitions. The first transition corresponds to the 
DNA Duplex Strand invasion  D-Loop
PNA-DNA-PNA
     Triplex
PNA
or with JW strand
Janus Wedge
   Triplex 
or JW PNA
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transition from triplex structure to DNA plus PNA. The second transition 
accounted for the melting of DNA duplex to two single-stranded random coil 
transitions.  
 Gel electrophoresis studies- These studies showed that the PNA can form the 
triplex and the mobility of the triplexes is slower than the DNA duplexes. 
Titration studies can be done to determine the Kd values of these bindings. 
 Orientation of PNA in binding- It can be determined by tethering a phenanthroline 
residue to the N-terminus followed by the addition of CuSO4 and a thiol that 
results in cleavage of DNA18. The general conclusion was the PNA binds anti-
parallel with respect to the DNA strand to which it binds stronger than the other 
strand. 
4.3. Limitation with pyrimidine-like Jw triplexes 
If the two Jw residues W1 and W2 are each capable of recognizing two base pair targets, 
then in principle we can form triplexes at virtually any target sequence.  The 
disadvantage to using such a format is the reduced ability to selectively target a single 
binding site within a large background of DNA sequences (since this motif may simply 
be unable to differentiate, for example dA-dT and dT-dA). This is illustrated in Figure 
4.6. These Jw residues can, in principle, recognize only two base pairs since an 180ᵒ 
rotation permits one residue to recognize G-C/C-G and the second to recognize A-T/T-A 
base pairs, although in practice these derivatives may bind with higher affinity to one of 
the A-T/T-A targets (and G-C/C-G targets). 
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Figure 4.6. Specificity limitation using pyrimidine-like Jw triplexes. 
In order to eliminate this targeting disadvantage, we need four Jw residues for the 
targeting of each of the four base pairs. Selective base pair targeting will rely upon the 
use of a purine-like of base for the Jw residue (Figure 4.7).  Since purines have a strong 
preference for the anti-conformation, a given purine residue as a nucleoside should 
exhibit preferential binding at only one of two possible base pair targets; it would need to 
undergo an anti- to syn- conformational change – an unlikely event – in order to target 
the second base pair.  This difference is likely not as strong in the PNA oligomers, 
although an anti-conformation, in which the bulk of the purine heterocycle is oriented 
away from the backbone, may still be preferred.  In any case, the use of the N7-alkylated 
PNA monomers, and the inherent geometry of the N7 vs. N9 alkylated products will 
ensure that competing Watson-Crick interactions are largely absent. 
 
Figure 4.7. Specificity may be achieved by using purine-like Jw residues. 
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With this rationale, we designed four purine-like resides retaining all the required 
conditions; i.e. with PNA as backbone and bases with correct hydrogen bond forming 
profile (Scheme 4.1). Residue A, B, C and D were envisioned to bind T-A, A-T, C-G and 
G-C respectively. We decided to prepare the modified bases separately with appropriate 
protecting groups followed by attaching to the PNA backbone (Scheme 4.1).  
 
Scheme 4.1. The common strategy to synthesize the PNA monomers. 
4.4. Preparation of Monomer to target T-A base pair (Y1)* 
The Jw triplex for targeting T-A is presented in Figure 4.8. This derivative could form 
four hydrogen bonds as a triplet. An addition hydrogen bond could be possible by 
protonation – the proton shared between the N3-nitrogen of the Jw residue and the N1-
nitrogen of the target dA residue.  The pKa of the N1-nitrogen of dA has been estimated 
as 3.9, but this value should increase with the proximity of second protonatable nitrogen 
in the triplex complex – the N3-nitrogen of the Jw residue. The presence of two exocyclic 
amino groups and no carbonyls may also assist in raising the apparent pKa of the N3-
nitrogen of this Jw residue. 
                                                          
* The compound numbers are reset here for the rest of the Chapter 4. 
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Figure 4.8. The Jw triplet for the T-A target. 
The preparation of the monomer (Scheme 4.2) started with 2,6-diaminopurine by 
following the literature19 under basic condition to yield 9-benzyl-2,6-diaminopurine (1). 
The reaction was clean and we got only the desired regioisomer. This was confirmed by 
the crystal structure (Figure 4.9A). Attempts were made to protect the two amino groups 
at this stage with Cbz-group. For this, CbzCl was used in different combinations of 
solvents, temperature and time. We had little to no success in protecting the amino 
groups. A more reactive alternative, Cbz-imidazole was tested. The yields were 
inconsistent. The maximum yield of mono-protected product that we obtained was only 
17%. We never obtained the di-protected product. This led us to investigate whether 
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these amino-groups are unreactive enough under peptide synthesis conditions to interfere 
during the PNA synthesis. So we reacted compound 1 with the PNA backbone in the 
presence of HBTU and DIPEA in DMF. The reaction clearly showed that it was reacting. 
It proved that we have to protect the amino-groups efficient to move forward with the 
synthesis. The next choice was using mesitylenesulfonyl (Mts) group because this group 
has been used before in our lab for the synthesis of PNA containing Generation 1, W2 
residue. The yield of this reaction was encouraging. Further optimization of this step led 
us to realize that adding the solution of MtsCl in DCM slowly to the solution of 
compound 1 in pyridine gave the best and consistent yield of mono-protected product (2). 
It was difficult to determine whether C2 or C6-amino was getting protected. It was later 
established that the structure was indeed compound 2.       
Scheme 4.2: Synthetic scheme of Y1. 
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It was a little puzzling that we could not detect any di-protected product. So once again 
we performed peptide coupling reaction of compound 2 with the PNA backbone. No 
reaction was observed at all which led us to believe that the C6-amino group was 
unreactive and will not interfere using the PNA synthesis. As a result, further attempts to 
obtain di-protected product were not pursued. 
According to our design, we needed to install the linker at N7 of compound 2. To do that 
compound 2 was reacted with BrCH2COOBu
t. It was a difficult step because we were 
trying to make a highly polar salt. When the reaction was carried out in DMF at elevated 
temperature (not more than 85 ᵒC), we obtained 30-32% of the product (3) consistently. 
Heating any higher resulted in decomposition of the material. Mixtures of solvents were 
investigated. The best possible yield (52%) was obtained in 1:1 mixture of DMF and 
dioxolane. The yields still vary. We think the reason is the difficulty in the isolation of 
the product. We were also able to obtain the crystal structure of the molecule (Figure 
4.9B). This also settled the regioselectivity of the mono-protected compound (2). 
 
Figure 4.9. Crystal structure of compound 1 (A) and 3 (B). 
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The next step was to remove the benzoyl group at the N9-position. One of the ways to 
remove a benzyl group from an amine is a hydrogenation reaction in the presence of 
Pd/C. In the first attempt, the hydrogen gas was bubbled at 1 atmospheric pressure 
through a solution of compound 3 in mixture of 1:1 methanol and water at 50 ᵒC20. A 
trace amount of desired product was obtained, while most of the starting material was 
recovered. Higher pressure of hydrogen gas and higher temperature were used. We 
observed no considerable improvement. Hydrogenation can also achieved by in situ 
hydrogen gas generation21. Following this methodology we were able to obtain 48-52% 
yield. Anhydrous methanol was used as the solvent. It is to be noted that if the reaction 
conditions were not anhydrous then the yield decreases significantly. The reaction also 
produced 10-15% methyl ester (instead of tert-butyl ester of compound 4). Changing the 
solvent to tert-butanol actually improved the yield to around 70%.  
To attach the modified residue to the PNA backbone, the butyl-ester (4) was hydrolyzed 
to its corresponding acid (5) using TFA. Coupling the acid (5) with the backbone was 
carried out employing HBTU (or HATU) and DIPEA in DMF in excellent yield. This is 
followed by the removal of the tert-butyl ester of the backbone to yield compound 8. This 
molecule was ready to be used as monomer to synthesize the PNA. 
4.5. PNA Synthesis incorporating Y1 
Synthesis of PNA oligomers has been carried out using a variety of monomers and 
coupling conditions22. Yields of oligomers depend on several factors, including the type 
of activator, the reaction time, the monomer excess, the pre-activation time, the times the 
coupling is repeated, the length of the oligomers and the temperature23. Syntheses of 
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sequences with a high content of purines often give poor yields due to the difficulty of 
coupling hindered monomers. The synthesis by Fmoc chemistry of PNA oligomers relies 
on the protocol developed by Egholm and Casale for the automated synthesis of PNA 
oligomers. In this protocol 5 equivalent of PNA monomer is initially pre-activated with 
HATU (4 equivalent) in the presence of the bases DIPEA (5 equivalent) and 2,6 lutidine 
(7.5 equivalent) and coupled for 20 min24. Although, this protocol works well under 
automated solid-phase PNA synthesis, when the same procedure is used for manual 
synthesis it requires much more equivalent of PNA monomer (3-8 equivalent) and time 
(1-6 hr per coupling). One of the efficient modified protocols was found to be- 2.5 
equivalent of PNA, 2.5 equivalent of HOBT/HBTU, 5 equivalent NMM, pyridine (40% 
of the total coupling volume) with the coupling time of 30 min25. We used this protocol 
to synthesize our PNA strands. Overall the PNA synthesis cycle is presented in Figure 
4.10. The details of the protocol will be discussed in the experimental section of the 
chapter. 
 
Figure 4.10. PNA synthesis cycle26. 
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We had to perform the solid-phase synthesis manually because the solubility of our PNA 
monomer (Y1) was poor and could not be used in peptide synthesizer. The first full 
length PNA that we decided to prepare is presented in Figure 4.11. 
 
Figure 4.11. PNA sequence with 15 Y1 residues. 
The sequence had a lysine residue at the C-terminus and two acridine groups at the N-
terminus. The purpose of the lysine is to increase the solubility of PNA in water and the 
binding rate27. Most probably the increased cationic character of the PNA ensures a high 
local concentration of the PNA in proximity to the DNA. Acridines were included 
because they are widely used in PNAs as intercalators. They help PNA by reversibly 
binding to the DNA duplex. The core of the sequence consists of 15 Y1 units to make 
sure the PNA binds with high stability without compromising the sequence specificity. 
Since it is a challenging and time-consuming task to prepare these monomers, we decided 
to synthesize a model PNA which had all the necessary linkages of monomers as our 
desired PNA sequence (Figure 4.11). The model sequence had the lysine to Y1 
connectivity, Y1 to Y1 connectivity and Y1 to acridine connectivity (Figure 4.12).  
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Figure 4.12. Model PNA sequence. 
The model PNA was synthesized following the above discussed protocol. The HPLC 
traces were clean and mass spectrometry proved that we had our PNA. With this result in 
hand we decided to synthesis our desired PNA following the same protocol. We 
increased the coupling time from 30 min to an hour from the 8th to the 12th coupling. For 
the rest of the coupling, the coupling time was 2.5 hr. 
The crude PNA was purified by reverse phase HPLC. Mass spectrometric analysis 
showed that there were peaks for various multiply-charged species of our sequence. But it 
also had multiply charged peaks for a species that has a molecular mass about 98 units 
more than our sequence. At this point we are trying to find proper conditions to separate 
these two species and characterize them. Once we can achieve it, we can move forward 
and perform binding studies with DNA duplexes. 
4.6. Preparation of Modified Base to target A-T base pair 
The molecule structurally is N7-alkylated 8-oxoguanine derivative. It is capable of 
forming five hydrogen bonds in the triplex structure (Figure 4.13).     
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Figure 4.13. The Jw triplet for the T-A target. 
Multiple routes were tried to synthesize this molecule. Some of them failed and some of 
them had very polar intermediates that were difficult to work with. We had issues with 
solubility, methods of isolation and characterization of products while attempting to 
synthesize this monomer. 
The guanosine can be converted to N9-benzyl guanine by treating the former with benzyl 
bromide in DMSO followed by hydrolysis using 10% aq. HCl solution28. Following this 
procedure, we attempted to protect the three hydroxyls of the guanosine (9) by TBS 
group followed by protection of C2-amino group by Cbz group (10) (Scheme 4.3). 
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Alkylation on N7 of compound 10 was attempted by a variety of alkyl haloacetates 
followed by hydrolysis. The solvent, temperature and time of the reaction were screened. 
Unfortunately, we could not isolate the desired product. In most of the cases, the 
compound decomposed and could not be characterized. The only exception was when we 
reacted 9 with ethyl bromoacetate in the presence of AgOTf as additive. Ag+ has a high 
affinity towards bromide and chloride. As a result Ag+ increases the electrophilicity of 
the methylene carbon attached to bromide of ethyl bromoacetate. However, the yields 
were inconsistent and always below 25%. We decided to move forward using the 
material (11a) for the next step.    
 
Scheme 4.3. Synthesis of the Jw base to target A-T base pair 
Guanosine can be converted to their 8-bromo derivative by stirring the starting material 
with saturated bromine water29. The bromo group can be changed to benzyloxy group by 
using sodium salt of benzyl alcohol, which can be further transformed to 8-oxo derivation 
under hydrogenation conditions30 (Scheme 4.4). So we were hoping to that similar 
methodology can be applied to 11a. Unfortunately, we could never brominate the 8-
position of 11a. As a result, the subsequent steps could not be explored. 
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Scheme 4.4. Methodology to prepare 7,8-dedihrdro-8-oxo-2’-deoxyguanosine. 
Another route was to alkylate the N7 of the 8-bromo or 8-benzyloxy derivative of 
guanosine or 2-deoxyguanosine. These routes were investigated in details but nothing 
encouraging was observed. Unfortunately, we never detected the desired product. In 
some cases, the glycosydic bond was cleaved, and in other cases the compound 
decomposed. An example of one of the routes is presented in Scheme 4.5.  
 
Scheme 4.5. Attempt to alkylate N7 of 8-benzyloxy-guanosine and 8-benzyloxy-2’-
deoxyguanosine. 
 
Instead of starting with guanosine or 2-deoxyguanosine, guanine was also used as starting 
material. We tried to alkylate the N7 of the guanine employing different reaction 
conditions and reagents. Even attempts to protect the C2-amino group failed. It was soon 
realized that guanine is too polar to be dissolved, even partially, in the organic solvent to 
perform the reactions.  
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With all this information we had, we designed the Scheme 4.6 which ultimately led us to 
obtain the required molecule. 
 
Scheme 4.6. Synthesis of the Jw base to target A-T base pair 
It started with the bromination of 9. The hydroxyls can be protected by acetate followed 
by the cleavage of the glycosydic bond31 to afford 16. It was realized that the protecting 
step can be avoided by directly cleaving the glycosydic bond under the similar condition. 
Compound 16 was then allowed to react with tert-butyl bromoacetate. We observed that 
there were two very close spots on the TLC. It was expected that we will get two 
regioisomers at this stage. We needed the N7 regioisomer for our synthesis. But it was 
difficult to determine which one of the two products was the N7 since the NMR spectra 
were similar. Fortunately, we were able to crystalize one of the products and it turned out 
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to the N9 product (Figure 4.14). It was the major product as well. Nevertheless we moved 
forward with minor N7 product and hydrolyzed it by refluxing it with sodium acetate in 
acetic acid to install the 8-oxo derivative (19). This molecule is yet to be coupled with the 
PNA backbone to generate the monomer required to be used in the PNA synthesis. 
 
Figure 4.14. Crystal structure of compound 18. 
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4.7. Preparation of Modified Base to target C-G base pair 
 
Figure 4.15. The Jw triplet for the C-G target. 
This Jw residue should be able to form four hydrogen bonds (Figure 4.15). It has been 
established that organic fluorides can act as hydrogen bond acceptors 32. So we expect the 
fifth hydrogen bond between the C2-fluorine atom of the Jw residue and the C2-amino 
group of the 2’-deoxyguanosine will be weak. Nevertheless, it might help targeting C-G 
pair over A-T base pair. From the synthetic point of view, this residue can be derived 
from the compound 17. 
The first step is to regenerate the free C2-amino group of compound 17. Heating 
compound 17 with piperidine in a 1:1 mixture of ethanol and adetonitrile yielded 20 in 
excellent yield. The next step is to diazotize the amino group and replaces it by fluoro 
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group (21). We have not been able to do this step yet. A thorough investigation is 
ongoing. Once that step is standardized, the next step would be to convert 8-bromo (21) 
to 8-oxo derivative (22).    
Scheme 4.7. Synthesis of compound 21, Jw residue to target C-G. 
An alternative Jw residue to target C-G base pair would be compound 23.  
Although it is not purine-like residue but it has the correct hydrogen bond 
forming profile. To synthesis this molecule Scheme 4.8 was proposed. 
Compound 24 was heated with maleic anhydride to produce compound 24 (Scheme 
4.8)33. The next step was to oxidize 25 to give us compound 23. We hypothesized that 
since the oxidation of 25 to 23 will result in extension of conjugation, this reaction should 
be facile. A variety of oxidizing agents and conditions were tried. Unfortunately, we 
never observed any product. As a result, this route has not been pursued any more. 
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Scheme 4.8. Top- Attempt to synthesize compound 22. Bottom- Mechanism of first step. 
4.8. Attempt to Synthesize Modified Base to target G-C base pair 
 
Figure 4.16. The Jw triplet for the G-C target. 
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Structurally the Jw residue (30) is N7 alkylated isoguanine derivative. The expected 
mode of Jw triplex formation is presented in Figure 4.16. The insolubility of isoguanine 
discouraged us to start the synthesis using it. We proposed Scheme 4.9 to prepare the 
monomer. The scheme starts with N9 benzylation of 2,6-diaminopurine (the step that we 
have optimized during the synthesis of Y1). The next step is to diazotize the C2-amino 
group to install the oxygen (26). The step has not been standardized yet. Due to pure 
solubility we had trouble characterizing it as well. Fortunately we were able to get the 
crystal structure of the molecule which confirmed the oxygen is at C2 and not C6 (Figure 
4.17).   
 
Scheme 4.9. Proposed route to synthesize the Jw residue (25) to target G-C 
The rest of the scheme is yet to be performed. We are hopeful about it because most of 
the steps have been done for the synthesis of Y1. To decrease the polarity and the 
nucleophilicity of C2 oxygen of 26, DPC can be installed (27). This can be followed by 
the alkylating the N7 of 27 to prepare the salt, 28. This needs to be followed by the 
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debenzylation and hydrolysis of ester to synthesize 30. This synthesis is under 
investigation and hopefully we will succeed soon.  
 
Figure 4.17. Cyrstal structure of compound 26. 
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4.9. Experimental and Methods 
Compound 2: Compound 1 (4.0 g, 16.65 mmol) was co-evaporated with pyridine (2×50 
mL). It was then dissolved in pyridine (160 mL) and mesitylene sulfonyl chloride (8.0 g, 
36.63 mmol) dissolved in DCM (180 mL) was added to it using a dropping funnel. After 
24 hours, there was trace amount of starting material. Another 1 equivalent of  mesitylene 
sulfonyl chloride (3.64 g) dissolved in DCM (18 mL) was added. The reaction was 
completed after another 4.5 hours. The solvent was removed under high vacuum. The 
residue was dissolved in chloroform and washed with water three times. The organic 
layer was collected, dried over anhydrous Na2SO4, filtered and and concentrated in 
vacuo. The resulting residue was purified by flash column chromatography (4.5:95.5 
MeOH:DCM) to yield light yellowish white amorphous powder as compound 2 (5.14g, 
73%). Rf = 0.58 (1:9 MeOH:DCM). 
1H NMR (500 MHz, DMSO-D6) δ 7.97 (s, 1H), 7.28 
– 7.20 (m, 3H), 7.04 – 7.00 (m, 2H), 6.88 (s, 2H), 5.10 (s, 2H), 2.64 (s, 6H), 2.18 (s, 3H). 
13C NMR (126 MHz, DMSO-D6) δ 153.07, 150.23, 146.00, 141.10, 139.55, 138.70, 
137.04, 131.16, 128.50, 127.57, 127.22, 45.53, 22.41, 20.42. HRMS (DART-TOF) calcd 
for [M + H]+ 423.16032, found: 423.16106. 
Compound 3: Compound 2 (4.50 g, 10.65 mmol) was dissolved in a 1:1 mixture of 
anhydrous DMF (100 mL) and dioxolane (100 mL). To this BrCH2COOBu
t (12.6 mL, 
85.20 mmol) was added dropwise. The solution was heated at 85 ᵒC for 18 hours when 
the starting material was completely consumed. The solvent was removed under high 
vaccum. The crude material was purified by solid pack flash column chromatography 
(7.5:92.5 MeOH:DCM) to yield white amorphous powder as compound 3 (3.0 g, 45%). 
Rf = 0.22 (1:9 MeOH:DCM). 
1H NMR (500 MHz, DMSO-D6) δ 11.76 (s, 1H), 9.47 (s, 
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1H), 7.72 (s, 2H), 7.39 – 7.32 (m, 3H), 7.15 (dt, J = 3.6, 2.7 Hz, 2H), 6.94 (t, J = 2.8 Hz, 
2H), 5.46 (s, 2H), 5.32 (d, J = 6.6 Hz, 2H), 2.64 (d, J = 3.8 Hz, 6H), 2.20 (s, 3H), 1.37 (s, 
9H). 13C NMR (126 MHz, DMSO-D6) δ 165.09, 155.12, 152.52, 148.98, 142.05, 141.37, 
138.88, 134.17, 133.93, 131.47, 128.85, 128.59, 127.90, 106.45, 83.34, 50.24, 47.47, 
27.47, 22.26, 20.47. HRMS (ESI-TOF) calcd for [M] 537.22785, found: 537.22900. 
Compound 4: Compound 3 (2.50 g, 4.05 mmol), ammonium formate (1.28 g, 20.25 
mmol) and 1% Pd/C (2.50 g) were taken in tert-butanol (40 mL). The mixture was 
refluxed for 2 hr. The TLC indicated that the starting material was consumed. The 
solution was filtered hot and washed twice by hot methanol. The filtrate was allowed to 
cool down to room temperature. The solvent was removed under high vacuum. The crude 
material was purified by flash column chromatography (4:96 MeOH:DCM) to yield 
white amorphous powder as compound 4 (1.12g, 62%). Rf = 0.47 (1:9 MeOH:DCM). 
1H 
NMR (500 MHz, DMSO-D6) δ 10.81 (s, 1H), 8.02 (s, 1H), 6.94 (s, 2H), 6.51 (s, 1H), 
5.21 (s, 2H), 2.70 (s, 6H), 2.21 (s, 3H), 1.36 (s, 9H). 13C NMR (126 MHz, DMSO-D6) δ 
174.12, 166.03, 154.01, 150.61, 148.96, 125.06, 120.36, 104.99, 83.43, 45.83, 28.01, 
24.22 (Please note that two expected peaks are missing even after 20000 scans). HRMS 
(DART-TOF) calcd for [M + H]+ 447.18145, found: 447.18221. 
Compound 5: Compund 4 (1.0 g, 1.30 mmol) was taken in DCM (13 mL) and cooled 
down to 0 ᵒC. TFA (13 mL) was added dropwise when the solution slowly became clean 
and pale yellow. The temperature was allowed to warm up to the room temperature. After 
7 hr, the reaction was completed. The solvent was removed and the product was 
precipitated out by adding diethyl ether. It was centrifuged and the solid was washed with 
diethyl ether twice. The white solid was characterized as product 5 (830 mg, 95%). 1H 
181 
 
NMR (500 MHz, DMSO-D6) δ 8.16 (s, 1H), 6.94 (s, 2H), 6.68 (s, 2H), 5.23 (s, 2H), 2.70 
(s, 6H), 2.21 (s, 3H). 13C NMR (126 MHz, DMSO-D6) δ 170.00, 153.40, 152.15, 146.57, 
141.54, 139.61, 135.83, 131.63, 108.28, 48.12, 22.93, 20.86. 
Compound 7: Compound 5 (750 mg, 1.92 mmol), 6 (755 mg, 1.75 mmol) and HBTU 
(796 mg, 2.10 mmol) were taken in DMF. To this DIPEA (0.67 mL, 3.85 mmol) was 
added. It was stirred at ambient temperature for 24 hr when the TLC indicated the 
completely consumption of compound 6. The solvent was removed under high vaccum. 
The crude material was purified by flash column chromatography (2.5:97.5 → 4.5:95.5 
MeOH:DCM) to yield yellowhish-white  foam as compound 7 (1.40 g 95%). Rf = 0.52 
(1:19 MeOH:DCM). HRMS (ESI-TOF) calcd for [M + H]+ 769.312643, found: 
769.31320. 
Compound 8: Compund 7 (1.0 g, 1.30 mmol) was taken in DCM (13 mL) and cooled 
down to 0 ᵒC. TFA (13 mL) was added dropwise when the solution slowly became clean 
and pale yellow. The temperature was allowed to warm up to the room temperature. After 
4 hr, the reaction was completed. The solvent was removed and the product was 
precipitated out by adding diethyl ether. It was centrifuged and the solid was washed with 
diethyl ether twice. The white solid was characterized as product 8 (870 mg, 94%). 
HRMS (ESI-TOF) calcd for [M + H]+ 713.250042, found: 713.25010. 
PNA Synthesis 
The PNA molecules were synthesised on Fmoc-protected MBHA resin with a loading 
capacity of about 0.54 mmol/g. After swelling 70 mg of the resin for 15 min DMF in the 
fritted column, the coupling cycle was started with the cleavage of the Fmoc-protection 
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groups. This was done by two successive incubations (5 min each) with 3 ml 20% 
piperidine in DMF solution. The Fmoc groups and piperidine were washed away six 
times with 3 mL DMF followed by a double coupling (30  min each) of the first 
monomer. Each of the two coupling solutions consisted of 2.5 equivalent of required 
monomer (67 mg of PNA monomer or 44 mg of Fmoc-Lys-Boc or 60 mg of Fmoc-
acrydine monomer or 29 mg of terminal acrydine monomer), 2.5 equivalent of HBTU (36 
mg) and HOBt (13 mg) dissolved in 1.37 mL DMF and 150 µL of NMM solution 
(0.2(M) NMM in pyridine). After coupling, the resin was washed six times with 3 mL 
DMF. It was followed by capping by capping solution (acetic anhydride/2,6-
lutidine/DMF in 5/6/89 ratio by volume) for 5 min.. Finally the resin was washed another 
six times with 3 mL DMF. The cycle was repeated until the synthesis of the desired PNA 
sequence was completed. The terminal Fmoc group was removed as described above. 
The resin was washed another six times with 3 mL of DMF and ten times with 3 mL of 
DCM. The resin was dried under flowing nitrogen gas. 
After synthesis, the final PNA molecules were cleaved from the dried resin by incubating 
10 mg of resin in 100 µL thioanisol and 50 µL 1,2-ethanedithiol at 0 ᵒC for 10 min. 650 
µL of TFA was added to the solution and kept for another 10 min at 0 ᵒC. To this mixture 
200 µL trifluoromethane sulfonic acid was added and the solution was kept at 0 ᵒC for 10 
min. It was allowed to warm up to room temperature and kept for another 2 hr. The 
solution was filtered and the resin was washed with TFA (2×250 µL). Precipitation of 
PNAs was done by adding 5 ml of ice-cold diethyl ether. PNAs were washed another 
time with ether, dried and dissolved in 20 mL water. It was then purified by reverse phase 
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semi-prep HPLC. Quality control of all synthesized PNAs was done by MALDI-TOF 
mass spectrometry. 
Compound 16: Compound 15 (3.0 g, 8.28 mmol) was suspended in acetic anhydride (21 
mL) at room temperature. To this H3PO4 (0.16 mL) was added. The solution was heated 
at 100 ᵒC for 1 hr. The solution became clear after 15 minutes and then slowly white 
precipitate started crushing out of the solution. After the reaction, the solution was 
filtered and the residue was washed with acetone (2×75 mL). The off-white residue was 
characterized as product 16 (2.0 g, 89%). 1H NMR (500 MHz, DMSO-D6) δ 12.03 (s, 
1H), 11.62 (s, 1H), 2.16 (s, 3H). 13C NMR (126 MHz, DMSO-D6) δ 173.88, 153.14, 
148.03, 123.83, 118.98, 24.18. HRMS (DART-TOF) calcd for [M + H]+ 271.97831, 
found: 271.97827. 
Compound 17: Compound 16 (1.75 g, 6.43 mmol) and sodium hydride (283 mg of 60% 
NaH dispersed in mineral oil, 7.07 mmol) were taken in anhydrous DMF (60 mL). The 
solution was stirred at room temperature for 30 min. To this BrCH2COOBu
t (1.05 mL, 
7.07 mmol) was added dropwise and the mixture was allowed to stir for 3 hr. The TLC 
indicated the complete consumption of starting material. The solvent was removed under 
high vacuum. The crude material was purified by solid pack gravity column 
chromatography (2.5:97.5 → 3:9 MeOH:DCM) to yield white powder as required 
compound 17 (745 mg, 30%) (Rf = 0.22; 2.5:7.5 MeOH:DCM) and N9 product, 
compound 18 (1.66 g, 67%) (Rf = 0.19; 2.5:7.5 MeOH:DCM).  Characterization of 
compound 17: 1H NMR (500 MHz, DMSO-D6) δ 5.06 (s, 2H), 2.17 (s, 3H), 1.42 (s, 9H). 
13C NMR (126 MHz, DMSO-D6) δ 173.48, 165.73, 156.05, 151.62, 147.58, 131.39, 
113.80, 82.77, 48.19, 27.56, 23.70. HRMS (DART-TOF) calcd for [M + H]+ 386.04639, 
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found: 386.04783. Characterization of compound 18: 1H NMR of compound 11 (500 
MHz, CD3OD) δ 4.84 (s, 2H), 2.21 (s, 3H), 1.48 (s, 9H). 
13C NMR (126 MHz, CD3OD) δ 
174.94, 167.02, 156.32, 152.24, 149.99, 126.75, 121.23, 84.62, 46.57, 28.16, 23.85. 
HRMS (DART-TOF) calcd for [M + H]+ 386.04639, found: 386.04758. 
Compound 19: Compound 17 (650 mg, 1.68 mmol) and sodium acetate (1.10 g, 13.44 
mmol) were refluxed in acetic acid for 5 hr. After the reaction the solution was allowed to 
cool to room temperature. Acetic acid was removed under high vacuum. Denatured 
ethanol (150 mL) was added to the crude ad it was stirred at 40 ᵒC for 1.5 hr. Then the 
solution was filtered hot (2×50 mL). The white residue was characterized as compound 
19 (342 mg, 76%). 1H NMR (500 MHz, D2O) δ 4.50 (s, 2H), 2.27 (s, 3H). 
13C NMR (126 
MHz, D2O) δ 175.06, 174.88, 153.37, 151.08, 147.21, 145.43, 105.24, 44.93, 23.24. 
HRMS (DART-TOF) calcd for [M + H]+ 268.06819, found: 268.06771. 
Compound 20: Compound 17 (500 mg, 1.30 mmol) was taken in 1:1 mixture of ethanol 
(13 mL) and acetonitrile (13 mL). To this piperidine (0.32 mL, 3.25 mmol) was added 
and the solution was heated at 85 ᵒC for 2 hr. The solution was cooled to room 
temperature and then cooled to -20 ᵒC overnight. The product crashed out of the solution. 
It was collected by filtering the solution and washing the precipitate with ethanol. The 
white solid was characterized as compound 20 (410 mg, 92%). HRMS (DART-TOF) 
calcd for [M + H]+ 344.03583, found: 344.03663. I could not obtain the proton or carbon 
NMR spectra because of its extreme insolubility in any of the solvents or mixture of 
solvents. 
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1H NMR of Compound 2 
 
13C NMR of Compound 2 
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1H NMR of Compound 3 
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1H NMR of Compound 4 
 
13C NMR of Compound 4 
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1H NMR of Compound 5 
 
13C NMR of Compound 5 
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1H NMR of Compound 16 
 
13C NMR of Compound 16 
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1H NMR of Compound 17 
 
13C NMR of Compound 17 
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1H NMR of Compound 18 
 
13C NMR of Compound 18 
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1H NMR of Compound 19 
 
13C NMR of Compound 19 
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HPLC for the Model PNA sequence (Figure 4.12). 
 
The region 4 of the HPLC trace contained the desired PNA sequence. Region 5 had some 
impurity. The MALDI-TOF mass spectrometry of the pure PNA is below. 
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195 
 
HPLC for the PNA sequence (Figure 4.11). 
 
 
The region D of the HPLC trace contained the desired PNA sequence with impurity. The 
MALDI-TOF mass spectrometry of the pure PNA is below. 
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The circled masses corresponded to the multiply-charged PNA sequences. Unfortunately, 
the sample is not clean. We are trying to find a system to increase the purity on HPLC.   
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